zhongwei/gh-k-dense-ai-claude-scientific-writer-claude-scientific-writer
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

Initial commit

Browse Source
This commit is contained in:
Zhongwei Li
2025-11-30 08:30:18 +08:00
commit 74bee324ab
335 changed files with 147377 additions and 0 deletions
Download Patch File Download Diff File Expand all files Collapse all files

570
skills/clinical-reports/references/case_report_guidelines.md Normal file
View File

@@ -0,0 +1,570 @@
# Clinical Case Report Guidelines
## CARE Guidelines (CAse REport)
The CARE guidelines provide a framework for transparent and complete reporting of clinical cases. The CARE checklist ensures that case reports contain all necessary information for readers to assess the validity and applicability of the findings.
### CARE Checklist Items
#### Title (1 item)
**1. Title**
- Include the words "case report" or "case study" in the title
- Indicate the area of focus
- Be specific about the condition or intervention
- Examples:
- Good: "Delayed Presentation of Aortic Dissection Mimicking Pneumonia: A Case Report"
- Poor: "An Interesting Case"
#### Keywords (1 item)
**2. Keywords**
- Provide 2-5 keywords
- Use MeSH (Medical Subject Headings) terms when possible
- Facilitate indexing and search
ability
- Examples: "aortic dissection," "atypical presentation," "diagnostic imaging"
#### Abstract (4 items)
**3a. Introduction**
- What is unique about this case?
- Why is it worth reporting?
- 1-2 sentences
**3b. Patient's main concerns and important clinical findings**
- Primary symptoms
- Key physical examination or diagnostic findings
**3c. Main diagnoses, therapeutics interventions, and outcomes**
- Final diagnosis
- Key treatments
- Clinical outcome
**3d. Conclusion**
- What are the main takeaway messages?
- Clinical implications
**Abstract Length:** Typically 150-250 words, structured or unstructured depending on journal
#### Introduction (2 items)
**4. Background**
- Brief background on the medical condition
- Epidemiology if relevant
- Current understanding and management
- 2-4 paragraphs
**5. Why is this case novel?**
- What makes this case worth reporting?
- Unique presentation, diagnosis, or outcome
- Contribution to medical knowledge
- Literature gap being addressed
#### Patient Information (4 items)
**6. Patient demographics and other information**
- Age, sex, race/ethnicity (if relevant)
- Occupation (if relevant to case)
- Living situation (if relevant)
- Example: "A 45-year-old African American woman"
**7. Main symptoms of patient**
- Chief complaint
- Presenting symptoms
- Duration and characteristics
- Example: "Presented with sudden onset severe chest pain radiating to the back, associated with dyspnea"
**8. Medical, family, and psychosocial history**
- Relevant past medical history
- Medications and allergies
- Family history of relevant conditions
- Social history (smoking, alcohol, drugs, occupation)
- Prior treatments or interventions
**9. Relevant past interventions and outcomes**
- Prior hospitalizations
- Previous treatments for same or related conditions
- Outcomes of prior interventions
#### Clinical Findings (1 item)
**10. Describe the relevant physical examination findings**
- Vital signs
- Physical examination by system
- Pertinent positive findings
- Important negative findings
- Example:
- "Vital signs: BP 180/110 mmHg (right arm), 140/80 mmHg (left arm), HR 105 bpm, RR 24/min
- Cardiovascular: Diastolic murmur heard over left sternal border, diminished pulse in left radial artery
- Pulmonary: Decreased breath sounds in left lung base"
#### Timeline (1 item)
**11. Describe important dates and times in this case**
- Chronological summary of events
- Onset of symptoms
- Healthcare encounters
- Diagnostic procedures
- Interventions
- Outcomes and follow-up
**Timeline Format Options:**
1. **Table format:**
| Date | Event |
|------|-------|
| Day 0 | Onset of chest pain and dyspnea |
| Day 0, 2 hours | Presented to emergency department |
| Day 0, 4 hours | CT angiography performed, diagnosed with aortic dissection |
| Day 0, 6 hours | Emergency surgery performed |
| Day 7 | Discharged home in stable condition |
| Month 3 | Follow-up imaging shows complete healing |
2. **Figure/graphic timeline**
3. **Narrative timeline embedded in text**
#### Diagnostic Assessment (5 items)
**12a. Diagnostic methods**
- List all diagnostic tests performed
- Laboratory tests
- Imaging studies
- Procedures (biopsy, catheterization, etc.)
- Pathology results
- Genetic testing if applicable
**12b. Diagnostic challenges**
- Difficulty in reaching diagnosis
- Atypical presentations
- Misleading initial findings
- Time to diagnosis
**12c. Diagnostic reasoning**
- Differential diagnosis considered
- Clinical reasoning process
- Why certain tests were ordered
- How diagnosis was narrowed
**12d. Prognostic characteristics**
- Severity of condition
- Staging if applicable
- Risk factors
- Expected prognosis
**12e. Strengths and limitations of diagnostic approaches**
- Appropriateness of diagnostic methods
- Limitations of tests used
- Alternative approaches considered
#### Therapeutic Intervention (4 items)
**13a. Types of interventions**
- Pharmacological interventions (medications with doses, routes, duration)
- Procedural or surgical interventions
- Lifestyle interventions
- Psychosocial interventions
- Complementary/alternative therapies
- Preventive interventions
Example:
- "Labetalol IV drip initiated for blood pressure control
- Emergency open surgical repair of ascending aortic dissection performed
- Post-operative anticoagulation withheld
- Beta-blocker and ACE inhibitor initiated post-operatively"
**13b. Administration of interventions**
- Timing of interventions
- Setting (emergency, inpatient, outpatient)
- Healthcare providers involved
- Patient adherence
**13c. Changes to interventions**
- Modifications during course of treatment
- Dose adjustments
- Changes due to adverse effects
- Switches to alternative therapies
- Rationale for changes
**13d. Strengths and limitations**
- Why these interventions were chosen
- Evidence supporting interventions
- Alternatives considered
- Limitations or barriers to treatment
#### Follow-Up and Outcomes (2 items)
**14a. Clinician and patient-assessed outcomes**
- Objective clinical outcomes
- Laboratory or imaging results
- Functional outcomes
- Patient-reported outcomes
- Quality of life
- Adverse events or complications
**14b. Important follow-up diagnostic and other test results**
- Follow-up imaging
- Laboratory monitoring
- Functional assessments
- Long-term outcomes
- Time points of follow-up
#### Discussion (5 items)
**15a. Strengths and limitations**
- What makes this case valuable?
- Limitations in diagnosis or treatment
- Limitations of case report methodology
- Generalizability
**15b. Relevant medical literature**
- Comparison to similar published cases
- Relationship to current understanding
- Novel aspects compared to literature
- Number and quality of similar cases
**15c. Rationale for conclusions**
- Why these conclusions are drawn
- Strength of evidence
- Alternative explanations considered
**15d. Main takeaways**
- Clinical lessons learned
- Practical implications for clinicians
- Educational value
- Contribution to medical knowledge
**15e. Future research or clinical care**
- Questions raised by this case
- Suggestions for future research
- Implications for clinical practice
- Areas needing further investigation
#### Patient Perspective (1 item)
**16. Patient's perspective or experience**
- Patient's own description of experience
- Impact on quality of life
- Patient's priorities and preferences
- Satisfaction with care
- Direct quotes when appropriate (with consent)
Example: "The patient stated: 'I thought I was having a heart attack, but the pain was different than I expected. I'm grateful the doctors figured out what was wrong so quickly.'"
This section is optional but encouraged as it provides valuable patient-centered information.
#### Informed Consent (1 item)
**17. Informed consent statement**
- Document that informed consent was obtained
- Specify what consent covers (case details, images, etc.)
- State that consent is available for review
- For pediatric cases, document parental/guardian consent
- For deceased patients or those unable to consent, document proxy consent
Examples:
- "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal."
- "The patient provided written informed consent for publication of this case report. All identifying information has been removed to protect patient privacy."
- "Written informed consent was obtained from the patient's next of kin for publication of this case report as the patient was deceased at the time of manuscript preparation."
## Journal-Specific Requirements
### High-Impact Medical Journals
#### The Lancet
- Case reports rarely accepted (only if exceptional clinical significance)
- Prefer brief case reports (500-600 words, 1 figure)
- Structured abstract required
- Maximum 10 references
#### New England Journal of Medicine (NEJM)
- Clinical Problem-Solving format for diagnostic challenges
- Case Records of the Massachusetts General Hospital (CPC format)
- Brief case reports in Images in Clinical Medicine
- Strict word limits (typically <750 words for Images)
#### JAMA
- Brief case reports in Clinical Challenge format
- Focus on diagnostic reasoning
- Maximum 600 words
- 1-2 figures allowed
### Specialty Journals
#### BMJ Case Reports
- All case reports must follow CARE guidelines
- Structured abstract required
- Learning points section required (3-5 bullet points)
- Patient consent form required
- Word limit: 3000 words (excluding abstract and references)
#### Journal of Medical Case Reports
- Strictly follows CARE guidelines
- Open access publication
- Structured abstract: Background, Case presentation, Conclusions
- Timeline required
- Patient perspective encouraged
#### American Journal of Case Reports
- Open access
- Follows CARE guidelines
- Structured abstract required
- Minimum 1500 words
- No upper word limit
## De-identification and Privacy
### 18 HIPAA Identifiers to Remove
Complete list of protected health information (PHI) that must be removed for Safe Harbor de-identification:
1. **Names** - Patient name, family members' names, healthcare provider names
2. **Geographic subdivisions smaller than state** - Street addresses, cities, counties, ZIP codes (can keep first 3 digits if >20,000 people in area)
3. **Dates** - Exact dates of birth, admission, discharge, death (keep year or use intervals)
4. **Telephone numbers** - Any phone numbers related to patient
5. **Fax numbers**
6. **Email addresses**
7. **Social Security numbers**
8. **Medical record numbers**
9. **Health plan beneficiary numbers**
10. **Account numbers**
11. **Certificate/license numbers**
12. **Vehicle identifiers** - License plates, VINs
13. **Device identifiers and serial numbers** - Pacemakers, implants (unless generic)
14. **Web URLs**
15. **IP addresses**
16. **Biometric identifiers** - Fingerprints, voice prints, retinal scans
17. **Full-face photographs** - Must obscure or obtain consent
18. **Any other unique identifying characteristic or code**
### De-identification Best Practices
**Age Reporting:**
- For adults: Can use exact age or age ranges (e.g., "a woman in her 50s")
- For patients >89 years: Must aggregate (e.g., "a woman in her 90s" or ">89 years")
- For pediatric cases: Use months for infants, years for children
**Date Reporting:**
- Use relative time intervals instead of exact dates
- Example: "Three months prior to presentation..." instead of "On January 15, 2023..."
- Can keep year if needed for context
- Use "Day 0, Day 1, Day 2" for timelines
**Location:**
- State or country acceptable
- Remove city, hospital name, specific clinic
- Example: "A community hospital in the Midwest" or "A tertiary care center in California"
**Rare Conditions:**
- Very rare conditions may themselves be identifying
- Consider whether the combination of diagnosis, location, and timeframe could identify patient
- May need to be vague about certain details
**Images:**
- Crop or blur faces
- Remove jewelry, tattoos, or identifying marks
- Crop images to show only relevant clinical findings
- Consider using illustrations instead of photographs
- Black bars over eyes are NOT sufficient
- Get explicit consent for recognizable images
**Pathology and Imaging:**
- Remove patient identifiers from image headers
- Remove dates from images
- Remove medical record numbers from labels
## Writing Style and Language
### Clarity and Precision
**Use clear, specific language:**
- Good: "The patient's hemoglobin decreased from 12.5 g/dL to 7.2 g/dL over 48 hours"
- Poor: "The patient's blood count dropped significantly"
**Avoid ambiguous terms:**
- Instead of "several," specify the number
- Instead of "recently," give timeframe
- Instead of "significant," provide exact values and p-values if applicable
**Use active voice when appropriate:**
- Good: "We diagnosed the patient with acute appendicitis"
- Acceptable: "The patient was diagnosed with acute appendicitis"
### Professional Tone
- Objective and factual
- Avoid sensationalism
- Respectful toward patient and healthcare team
- Avoid value judgments
- Focus on clinical facts and medical reasoning
### Tense
- **Abstract**: Usually past tense
- **Introduction**: Present tense for background, past tense for case description
- **Case presentation**: Past tense
- **Discussion**: Present tense for established knowledge, past tense for this case
### Common Mistakes to Avoid
1. **Insufficient novelty** - Reporting common presentations without unique aspects
2. **Missing informed consent** - Failing to obtain or document consent
3. **Inadequate de-identification** - Leaving identifiable information
4. **Poor literature review** - Not contextualizing within existing knowledge
5. **Excessive length** - Including unnecessary details
6. **Lack of structure** - Not following CARE guidelines or journal format
7. **Overgeneralization** - Drawing broad conclusions from one case
8. **Missing timeline** - Not providing clear chronology
9. **Vague outcomes** - Not clearly describing clinical outcome
10. **No learning points** - Failing to articulate clinical lessons
## Learning Points Format
Many journals require a "Learning Points" or "Key Messages" section with 3-5 bulleted takeaways.
**Characteristics of good learning points:**
- Concise (1-2 sentences each)
- Clinically actionable
- Generalizable beyond this specific case
- Focus on diagnosis, treatment, or recognition
- Avoid overgeneralization
**Example:**
- "Aortic dissection can present with atypical symptoms that mimic pneumonia, including cough and dyspnea without chest pain."
- "Blood pressure differential between arms >20 mmHg should raise suspicion for aortic dissection."
- "CT angiography is the gold standard for diagnosing acute aortic dissection and should be performed urgently in high-risk patients."
## Literature Search Strategies
**Databases to search:**
- PubMed/MEDLINE
- Embase
- Google Scholar
- Scopus
- Web of Science
**Search terms:**
- Disease or condition name
- Key clinical features
- Treatment or intervention
- Use MeSH terms
- Combine with "case report" or "case series"
**When citing literature:**
- Cite most relevant and recent cases
- Include systematic reviews if available
- Cite original descriptions of rare conditions
- Balance supporting and contrasting evidence
- Typically 15-30 references for case report
## Ethical Considerations
### Informed Consent
**Required elements:**
- Purpose of publication
- What will be published (case details, images, outcomes)
- De-identification efforts
- Open access considerations (public availability)
- No effect on clinical care
- Right to withdraw
- Contact for questions
**Timing:**
- Best obtained during or shortly after clinical care
- Can be obtained retrospectively if patient available
- For deceased patients, next of kin consent
**Special situations:**
- Pediatric patients: Parent/guardian consent
- Incapacitated patients: Legal representative consent
- Deceased patients: Next of kin consent
- Patients lost to follow-up: Discuss with editor
### Authorship
**ICMJE criteria for authorship (all must be met):**
1. Substantial contributions to conception/design or acquisition/analysis/interpretation of data
2. Drafting or critically revising for important intellectual content
3. Final approval of version to be published
4. Agreement to be accountable for all aspects of the work
**Common authorship roles in case reports:**
- First author: Primary writer, often junior physician/trainee
- Senior author: Attending physician, supervisor
- Co-authors: Contributing specialists, consultants
- Acknowledgments: Contributors not meeting authorship criteria
## Submission Process
### Cover Letter Elements
- Brief introduction of the case
- Statement of novelty and significance
- Confirmation of CARE guideline adherence
- Statement that manuscript is not under consideration elsewhere
- Disclosure of any conflicts of interest
- Corresponding author contact information
### Required Documents
- Manuscript (following journal format)
- CARE checklist (completed)
- Patient consent form
- Copyright transfer agreement
- Conflict of interest disclosure
- ORCID iDs for all authors
- Cover letter
### Revision and Peer Review
**Common reviewer requests:**
- Expand literature review
- Clarify timeline
- Add more detail to diagnostics or treatment
- Improve discussion of pathophysiology
- Strengthen learning points
- Verify consent documentation
- Improve image quality
**Response to reviewers:**
- Address each comment point-by-point
- Provide line numbers for changes
- Justify if not making requested change
- Thank reviewers for feedback
- Proofread revised manuscript
## Case Report Formats by Type
### Diagnostic Challenge
Focus on diagnostic reasoning process, differential diagnosis, and key diagnostic clues.
### Rare Disease or Presentation
Emphasize rarity, epidemiology, and contribution to medical knowledge about the condition.
### Adverse Drug Reaction
Include drug details (dose, duration), timeline, causality assessment (Naranjo scale), and outcome after discontinuation.
### Treatment Innovation
Describe novel treatment approach, rationale, outcome, and comparison to standard treatment.
### Unexpected Outcome
Describe unexpected response to treatment or unusual disease course.
## Supplementary Resources
- CARE website: https://www.care-statement.org/
- CARE checklist: Available in multiple languages
- Example case reports: Review published cases in target journal
- Medical writing courses: Many institutions offer case report writing workshops
---
This reference provides comprehensive guidance for writing clinical case reports following CARE guidelines. Refer to this document when preparing case reports for journal submission, and use the CARE checklist to ensure completeness before submission.

693
skills/clinical-reports/references/clinical_trial_reporting.md Normal file
View File

@@ -0,0 +1,693 @@
# Clinical Trial Reporting Standards
## ICH-E3: Structure and Content of Clinical Study Reports
The International Council for Harmonisation (ICH) E3 guideline defines the structure and content of clinical study reports (CSRs) for regulatory submission.
### CSR Overview
**Purpose:**
- Provide comprehensive description of study design, conduct, and results
- Support regulatory decision-making
- Document evidence of safety and efficacy
**Audience:**
- Regulatory authorities (FDA, EMA, PMDA, etc.)
- Medical reviewers
- Statistical reviewers
- Clinical pharmacology reviewers
**Length:** Typically 50-300 pages (main text), with extensive appendices
### Main Sections of ICH-E3 CSR
#### Section 1: Title Page
**Required elements:**
- Full study title
- Protocol number and version
- Sponsor name and address
- Compound/drug name and code
- Study phase
- Indication
- Report date and version number
- Report authors
- Confidentiality statement
#### Section 2: Synopsis
**Length:** 5-15 pages
**Content:**
- Brief summary of entire CSR
- Must be understandable as standalone document
- Cover all major sections
**Standard synopsis elements:**
1. Study identifier and title
2. Study objectives
3. Methodology:
- Study design
- Number and description of patients
- Diagnosis and main criteria for inclusion
- Study treatments
- Duration of treatment
- Criteria for evaluation
- Statistical methods
4. Results:
- Number of patients enrolled, completed, discontinued
- Efficacy results
- Safety results
5. Conclusions
#### Section 3: Ethics
**3.1 Independent Ethics Committee/Institutional Review Board**
- Names and locations of all IRBs
- Dates of initial approval
- Dates of protocol amendment approvals
- Documentation of continuing review
**3.2 Ethical Conduct of Study**
- Statement of compliance with GCP and Declaration of Helsinki
- Protocol adherence
- Informed consent process
**3.3 Patient Information and Consent**
- Description of informed consent procedures
- Consent form versions used
- Process for re-consent if applicable
#### Section 4: Investigators and Study Administrative Structure
**4.1 Investigators**
- List of principal investigators by site
- Site addresses and enrollment
- Coordinating investigator (if applicable)
**4.2 Administrative Structure**
- Sponsor personnel and roles
- CRO involvement (if applicable)
- Monitoring procedures
- Data management organization
- Statistical analysis organization
**4.3 Study Monitoring and Quality Assurance**
- Monitoring procedures and frequency
- Source document verification
- Quality control procedures
- Audits performed
#### Section 5: Introduction
**5.1 Background**
- Disease or condition being studied
- Current treatment landscape
- Unmet medical need
**5.2 Investigational Product**
- Pharmacology and mechanism of action
- Nonclinical findings
- Prior clinical experience
- Known safety profile
**5.3 Non-Investigational Therapy**
- Comparator drugs or placebo
- Concomitant medications allowed/prohibited
#### Section 6: Study Objectives
**6.1 Primary Objective**
- Main research question
- Clearly stated and specific
- Example: "To evaluate the efficacy of Drug X compared to placebo in reducing HbA1c in patients with type 2 diabetes mellitus over 24 weeks of treatment"
**6.2 Secondary Objectives**
- Additional research questions
- Supportive efficacy endpoints
- Safety objectives
- Exploratory objectives
**6.3 Endpoints**
- Primary endpoint definition and measurement
- Secondary endpoints
- Safety endpoints
- Pharmacokinetic endpoints (if applicable)
- Biomarker endpoints (if applicable)
#### Section 7: Investigational Plan
**7.1 Overall Study Design and Plan**
- Study design type (parallel, crossover, factorial, etc.)
- Randomization and blinding
- Study phases or periods
- Duration of treatment and follow-up
- Dosing regimen
- Study flow diagram (patient flowchart)
**7.2 Sample Size**
- Target enrollment
- Sample size justification
- Power calculation assumptions:
- Expected effect size
- Variability estimates
- Type I error (alpha)
- Power (1 - beta)
- Drop-out rate assumptions
**7.3 Statistical Methods**
- Analysis populations (ITT, PP, safety)
- Handling of missing data
- Interim analyses (if planned)
- Multiplicity adjustments
- Subgroup analyses
- Sensitivity analyses
**7.4 Changes to Protocol**
- Protocol amendments and rationale
- Impact on study conduct and analysis
#### Section 8: Study Patients
**8.1 Inclusion and Exclusion Criteria**
- Key inclusion criteria
- Key exclusion criteria
- Rationale for criteria
**8.2 Demographic and Baseline Characteristics**
- Age, sex, race/ethnicity
- Disease severity or stage
- Prior therapies
- Baseline values of key endpoints
- Comparability across treatment groups
**8.3 Patient Disposition**
- Number screened
- Number randomized
- Number completing study
- Number withdrawn (by reason)
- Number lost to follow-up
- CONSORT flow diagram
**8.4 Protocol Deviations**
- Major protocol deviations
- Minor protocol deviations
- Impact on efficacy and safety analyses
- Corrective actions taken
**8.5 Demographic and Other Baseline Characteristics**
- Detailed demographic tables
- Baseline disease characteristics
- Stratification factors
- Medical history
- Prior/concomitant medications
#### Section 9: Efficacy Evaluation
**9.1 Data Sets Analyzed**
- Intent-to-treat (ITT) population
- Per-protocol (PP) population
- Modified ITT
- Other analysis sets
- Justification for population definitions
**9.2 Demographic and Baseline Characteristics**
- Demographics by analysis population
- Baseline comparability
**9.3 Measurements of Treatment Compliance**
- Drug accountability
- Pill counts or diary compliance
- Plasma drug levels (if measured)
- Percent of planned dose received
**9.4 Efficacy Results**
**9.4.1 Primary Endpoint**
- Results for primary endpoint
- Statistical analysis
- Effect size and confidence intervals
- P-values
- Subgroup analyses
**9.4.2 Secondary Endpoints**
- Results for each secondary endpoint
- Statistical analyses
- Hierarchy of testing (if applicable)
**9.4.3 Other Efficacy Endpoints**
- Exploratory endpoints
- Post-hoc analyses
- Responder analyses
**9.5 Dropouts and Missing Data**
- Patterns of missing data
- Reasons for dropout
- Sensitivity analyses for missing data
#### Section 10: Safety Evaluation
**10.1 Extent of Exposure**
- Duration of exposure
- Dose intensity
- Dose delays or reductions
- Treatment discontinuations due to adverse events
**10.2 Adverse Events**
**10.2.1 Overview of Adverse Events**
- Summary tables (any AE, treatment-related, serious, leading to discontinuation)
- Percentage of patients with AEs
- Comparison across treatment groups
**10.2.2 Common Adverse Events**
- AEs occurring in ≥5% or ≥10% of patients
- Sorted by frequency
- Preferred terms and system organ class (MedDRA)
**10.2.3 Serious Adverse Events**
- Definition of SAE
- Summary table of SAEs
- Individual narratives for each SAE
- Causality assessment
- Outcome
**10.2.4 Adverse Events Leading to Discontinuation**
- AEs leading to study drug discontinuation
- Frequency and type
- Relationship to study drug
**10.2.5 Deaths**
- All deaths during study and follow-up
- Detailed narratives for each death
- Relationship to study drug
- Autopsy findings (if available)
**10.3 Clinical Laboratory Evaluations**
- Laboratory abnormalities
- Shift tables (normal to abnormal, abnormal to normal)
- Mean changes from baseline
- Laboratory values meeting protocol-defined criteria
- Hepatotoxicity monitoring (if applicable)
**10.4 Vital Signs and Physical Findings**
- Vital signs (BP, HR, temperature, respiratory rate)
- Mean changes from baseline
- Clinically significant changes
- Physical examination findings
**10.5 ECG Evaluation**
- QTc interval changes
- Other ECG abnormalities
- Clinically significant ECG findings
**10.6 Special Safety Evaluations**
- Immunogenicity (for biologics)
- Pregnancy outcomes (if applicable)
- Abuse potential (if applicable)
- Withdrawal or rebound effects
- Dependency potential
#### Section 11: Discussion and Overall Conclusions
**11.1 Efficacy Discussion**
- Interpretation of efficacy results
- Clinical significance of findings
- Consistency with prior studies
- Limitations
**11.2 Safety Discussion**
- Safety profile overview
- Notable safety findings
- Comparison to known safety profile
- Risk-benefit assessment
**11.3 Benefit-Risk Assessment**
- Overall benefit-risk conclusion
- Subpopulations with favorable/unfavorable benefit-risk
- Implications for dosing or patient selection
**11.4 Clinical Implications**
- Place in therapy
- Target patient population
- Comparison to existing therapies
#### Section 12: Tables, Figures, and Graphs
Comprehensive set of tables and figures for efficacy and safety data.
**Common tables:**
- Demographic and baseline characteristics
- Patient disposition
- Extent of exposure
- Efficacy results (primary and secondary endpoints)
- Adverse event summary
- Common adverse events
- Serious adverse events
- Deaths
- Laboratory abnormalities
- Vital signs
**Common figures:**
- Study design schematic
- Patient disposition flowchart (CONSORT)
- Kaplan-Meier curves (survival, time to event)
- Forest plots (subgroup analyses)
- Mean change over time plots
#### Section 13: References
- Publications cited in CSR
- Relevant literature
- Regulatory guidelines
- Prior study reports
#### Section 14: Appendices
**Required appendices:**
- Study protocol and amendments
- Sample case report forms
- Investigator list with IRB information
- Patient information and informed consent forms
- List of patients receiving study drug
- Randomization scheme
- Audit certificates (if applicable)
- Documentation of statistical methods
- Publications based on study
**Optional appendices:**
- Individual patient data listings
- SAE narratives
- Laboratory normals and conversion factors
- Investigator signatures
### Statistical Analysis Plan (SAP)
**SAP Components:**
- Analysis populations
- Handling of missing data
- Statistical tests to be used
- Adjustment for multiplicity
- Interim analysis plan
- Subgroup analyses
- Sensitivity analyses
- Safety analyses
**SAP Timing:**
- Finalized before database lock
- Amendments documented with rationale
## CONSORT (Consolidated Standards of Reporting Trials)
CONSORT guidelines promote transparent and complete reporting of randomized controlled trials.
### CONSORT 2010 Checklist
#### Title and Abstract
- **1a. Title**: Identification as randomized trial in title
- **1b. Abstract**: Structured summary covering trial design, methods, results, conclusions
#### Introduction
- **2a. Background**: Scientific background and explanation of rationale
- **2b. Objectives**: Specific objectives or hypotheses
#### Methods - Participants
- **3a. Eligibility**: Eligibility criteria for participants
- **3b. Settings**: Settings and locations of data collection
#### Methods - Interventions
- **4a. Interventions**: Details of interventions for each group
- **4b. Details**: Sufficient details to allow replication
#### Methods - Outcomes
- **5. Outcomes**: Clearly defined primary and secondary outcome measures
- **6a. Sample size**: How sample size was determined
- **6b. Interim analyses**: When applicable, explanation of interim analyses
#### Methods - Randomization
- **7a. Sequence generation**: Method of random sequence generation
- **7b. Allocation concealment**: Mechanism of allocation concealment
- **8a. Implementation**: Who generated allocation, enrolled, and assigned participants
- **8b. Blinding**: Whether participants, care providers, outcome assessors were blinded
#### Methods - Statistical
- **9. Statistical methods**: Methods for primary and secondary outcomes
- **10. Additional analyses**: Subgroup or adjusted analyses
#### Results - Participant Flow
- **11a. Enrollment**: Numbers screened, randomized, allocated
- **11b. Losses and exclusions**: For each group, losses and exclusions after randomization
- **12. Recruitment**: Dates defining recruitment and follow-up periods
- **13a. Baseline**: Baseline demographic and clinical characteristics
- **13b. Baseline comparability**: Numbers analyzed in each group
#### Results - Outcomes and Estimation
- **14a. Outcomes**: For primary and secondary outcomes, results for each group
- **14b. Binary outcomes**: For binary outcomes, effect sizes and confidence intervals
- **15. Ancillary analyses**: Results of other analyses performed
#### Results - Harms
- **16. Harms**: All important harms or unintended effects in each group
#### Discussion
- **17a. Limitations**: Trial limitations, addressing biases, imprecision
- **17b. Generalizability**: Generalizability (external validity) of trial findings
- **18. Interpretation**: Interpretation consistent with results, balancing benefits and harms
- **19. Registration**: Registration number and name of trial registry
- **20. Protocol**: Where full trial protocol can be accessed
- **21. Funding**: Sources of funding, role of funders
### CONSORT Flow Diagram
Standard format showing patient flow through trial:
```
Assessed for eligibility (n=)
↓
Randomized (n=)
├─ Allocated to intervention (n=)
│ ├─ Received intervention (n=)
│ └─ Did not receive intervention (n=)
│ Give reasons
├─ Allocated to control (n=)
│ ├─ Received control (n=)
│ └─ Did not receive control (n=)
│ Give reasons
↓
Lost to follow-up (n=)
Give reasons
Discontinued intervention (n=)
Give reasons
↓
Analyzed (n=)
Excluded from analysis (n=)
Give reasons
```
## Serious Adverse Event (SAE) Reporting
### Definition of Serious Adverse Event
An adverse event or suspected adverse reaction is considered serious if it:
- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Requires intervention to prevent permanent impairment or damage (device-related)
- Other medically important events (based on medical judgment)
### SAE Report Components
**1. Administrative Information**
- Report type (initial, follow-up, final)
- Report number
- Date of report
- Reporter information
- Sponsor information
- Study identifier (protocol number, NCT number)
**2. Patient Information (De-identified)**
- Subject ID or randomization number
- Initials (if permitted)
- Age or date of birth (year only)
- Sex
- Race/ethnicity
- Weight
- Height
**3. Study Information**
- Study phase (I, II, III, IV)
- Study design (randomized, open-label, etc.)
- Treatment arm or randomization
- Date of first study drug
- Date of last study drug
**4. Event Information**
- Reported term (verbatim)
- MedDRA preferred term
- System organ class
- Date of onset
- Time of onset (if relevant)
- Date of resolution (or ongoing)
- Duration
**5. Seriousness Criteria**
- Death: Yes/No
- Life-threatening: Yes/No
- Hospitalization required: Yes/No
- Hospitalization prolonged: Yes/No
- Disability/incapacity: Yes/No
- Congenital anomaly: Yes/No
- Medically significant: Yes/No
**6. Severity**
- Mild: Noticeable but does not interfere with daily activities
- Moderate: Interferes with daily activities but manageable
- Severe: Prevents usual daily activities, requires intervention
Note: Severity ≠ Seriousness
**7. Outcome**
- Recovered/resolved
- Recovering/resolving
- Not recovered/not resolved
- Recovered/resolved with sequelae
- Fatal
- Unknown
**8. Causality Assessment**
- Relationship to study drug:
- Not related
- Unlikely related
- Possibly related
- Probably related
- Definitely related
- Relationship to study procedures
- Relationship to underlying disease
- Relationship to concomitant medications
- Reasoning for determination
**9. Expectedness**
- Expected (per Investigator's Brochure or protocol)
- Unexpected (not in IB or more severe than documented)
**10. Action Taken with Study Drug**
- No change
- Dose reduced
- Dose increased
- Drug interrupted (temporarily held)
- Drug discontinued
- Not applicable (event occurred after discontinuation)
**11. Treatments/Interventions for Event**
- Medications administered
- Procedures performed
- Hospitalization details
- ICU admission
- Surgical intervention
**12. Event Narrative**
- Detailed description of event
- Timeline of events
- Clinical course
- Relevant medical history
- Concomitant medications
- Diagnostic test results
- Treatment and response
- Outcome and current status
**Example narrative:**
```
A 58-year-old male (Subject ID: 12345) enrolled in Study XYZ-301, a Phase 3
randomized trial of Drug X vs. placebo for heart failure. On Day 42 of treatment
(15-Feb-2024), the patient presented to the emergency department with sudden onset
severe chest pain, diaphoresis, and dyspnea. ECG showed ST-segment elevation in
leads V2-V4. Troponin I was elevated at 12.5 ng/mL (normal <0.04). The patient was
diagnosed with acute ST-elevation myocardial infarction and underwent emergent
cardiac catheterization revealing 95% occlusion of the left anterior descending
artery. Percutaneous coronary intervention with drug-eluting stent placement was
performed successfully. The patient was admitted to the cardiac intensive care unit.
Study drug was permanently discontinued on Day 42. The patient recovered and was
discharged on Day 47 (20-Feb-2024) in stable condition. This event was assessed as
unlikely related to study drug by the investigator, as the patient had significant
underlying coronary artery disease risk factors including diabetes, hypertension,
and smoking history.
```
### Regulatory Reporting Timelines
**FDA IND Safety Reporting (21 CFR 312.32):**
- **Fatal or life-threatening unexpected SAEs**: 7 calendar days for preliminary report, 15 days for complete report
- **Other serious unexpected events**: 15 calendar days
- **Annual safety reports**: Within 60 days of anniversary of IND
**EMA Expedited Reporting:**
- **Fatal or life-threatening unexpected events**: 7 days initial, 8 additional days for complete report
- **Other unexpected serious events**: 15 days
**IRB Reporting:**
- Per institutional policy
- Typically 5-10 days for serious unexpected events
- Some institutions require reporting within 24-48 hours
### MedDRA Coding
**MedDRA (Medical Dictionary for Regulatory Activities):**
- Standardized medical terminology for regulatory communication
- Hierarchical structure:
- SOC (System Organ Class) - highest level
- HLGT (High Level Group Term)
- HLT (High Level Term)
- PT (Preferred Term) - used for coding AEs
- LLT (Lowest Level Term) - verbatim terms
**Example:**
- Verbatim term: "bad headache"
- LLT: Headache
- PT: Headache
- HLT: Headaches NEC
- HLGT: Neurological disorders NEC
- SOC: Nervous system disorders
### Causality Assessment Methods
**WHO-UMC Causality Categories:**
- **Certain**: Event cannot be explained by other factors
- **Probable/Likely**: Event more likely related to drug than other factors
- **Possible**: Event could be related to drug, but other factors cannot be ruled out
- **Unlikely**: Event likely explained by other factors
- **Conditional/Unclassified**: More data needed
- **Unassessable/Unclassifiable**: Information insufficient
**Naranjo Algorithm (for ADRs):**
Scoring system based on 10 questions:
- Score ≥9: Definite
- Score 5-8: Probable
- Score 1-4: Possible
- Score ≤0: Doubtful
## Data Safety Monitoring Board (DSMB)
**Purpose:**
- Independent review of safety data
- Monitoring benefit-risk
- Recommendations on study continuation
**DSMB Charter Elements:**
- Membership and qualifications
- Roles and responsibilities
- Meeting frequency
- Data reviewed
- Decision-making criteria
- Communication procedures
- Confidentiality
**DSMB Reports:**
- Open reports (all parties can see)
- Closed reports (DSMB and sponsor only)
- Recommendations: Continue, modify, or terminate study
---
This reference provides comprehensive guidance for clinical trial reporting following ICH-E3 and CONSORT guidelines, as well as SAE reporting requirements. Use these standards when preparing regulatory submissions and trial publications.

530
skills/clinical-reports/references/data_presentation.md Normal file
View File

@@ -0,0 +1,530 @@
# Data Presentation in Clinical Reports
## Tables for Clinical Data
### Table Design Principles
**General guidelines:**
- Clear, concise title describing table contents
- Column headers with units
- Row labels aligned left, data aligned appropriately (numbers right, text left)
- Footnotes for abbreviations, statistical notation, special cases
- Consistent decimal places (typically 1-2 for percentages, 1-3 for continuous variables)
- Consistent formatting throughout document
**Title placement:**
- Above table
- Numbered sequentially (Table 1, Table 2, etc.)
- Descriptive enough to stand alone
**Footnote symbols (in order):**
- *, †, ‡, §, ||, ¶, #
- Or use superscript letters (a, b, c...)
- Or use superscript numbers if not confused with references
### Demographic and Baseline Characteristics Table
**Purpose:** Describe study population at baseline
**Standard format:**
```
Table 1. Baseline Demographics and Clinical Characteristics
Characteristic Treatment Group Control Group Total
(N=150) (N=145) (N=295)
─────────────────────────────────────────────────────────────────────────
Age, years
Mean (SD) 64.2 (8.5) 63.8 (9.1) 64.0 (8.8)
Median (IQR) 65 (58-71) 64 (57-70) 64 (58-71)
Range 45-82 43-85 43-85
Sex, n (%)
Male 95 (63.3) 88 (60.7) 183 (62.0)
Female 55 (36.7) 57 (39.3) 112 (38.0)
Race, n (%)
White 110 (73.3) 105 (72.4) 215 (72.9)
Black/African American 25 (16.7) 28 (19.3) 53 (18.0)
Asian 10 (6.7) 8 (5.5) 18 (6.1)
Other 5 (3.3) 4 (2.8) 9 (3.0)
BMI, kg/m²
Mean (SD) 28.5 (4.2) 28.1 (4.5) 28.3 (4.4)
Baseline HbA1c, %
Mean (SD) 8.9 (1.2) 9.0 (1.3) 9.0 (1.2)
Disease duration, years
Median (IQR) 6 (3-10) 5 (3-9) 6 (3-10)
Prior medications, n (%)
Metformin 135 (90.0) 130 (89.7) 265 (89.8)
Sulfonylurea 45 (30.0) 42 (29.0) 87 (29.5)
Insulin 20 (13.3) 18 (12.4) 38 (12.9)
─────────────────────────────────────────────────────────────────────────
SD = standard deviation; IQR = interquartile range; BMI = body mass index;
HbA1c = hemoglobin A1c
```
**Key elements:**
- Sample size for each group (N=)
- Continuous variables: mean (SD), median (IQR), range
- Categorical variables: n (%)
- No p-values for baseline comparisons (debated but generally not recommended)
### Efficacy Results Table
**Purpose:** Present primary and secondary endpoint results
**Example:**
```
Table 2. Primary and Secondary Efficacy Endpoints at Week 24
Endpoint Treatment Control Difference P-value
(N=150) (N=145) (95% CI)
──────────────────────────────────────────────────────────────────────────────────
Primary Endpoint
Change in HbA1c from baseline, %
Mean (SE) -1.8 (0.1) -0.6 (0.1) -1.2 <0.001
95% CI (-2.0, -1.6) (-0.8, -0.4) (-1.5, -0.9)
Secondary Endpoints
Change in FPG, mg/dL
Mean (SE) -42.5 (3.2) -15.2 (3.4) -27.3 <0.001
95% CI (-48.8, -36.2) (-21.9, -8.5) (-36.4, -18.2)
% achieving HbA1c <7%
n (%) 78 (52.0) 25 (17.2) - <0.001
95% CI (43.9, 60.1) (11.4, 24.5)
Change in body weight, kg
Mean (SE) -3.2 (0.4) -0.5 (0.4) -2.7 <0.001
95% CI (-4.0, -2.4) (-1.3, 0.3) (-3.8, -1.6)
──────────────────────────────────────────────────────────────────────────────
SE = standard error; CI = confidence interval; HbA1c = hemoglobin A1c;
FPG = fasting plasma glucose
```
**Statistical presentation:**
- Point estimates with measures of precision (SE or CI)
- p-values (consider adjustment for multiplicity)
- Effect size (difference or ratio) with 95% CI
- Significance level noted (e.g., p<0.05, p<0.01, p<0.001)
### Adverse Events Table
**Purpose:** Summarize safety data
**Example:**
```
Table 3. Summary of Adverse Events
Event Category Treatment Control P-value
(N=150) (N=145)
n (%) n (%)
──────────────────────────────────────────────────────────────────────────
Any adverse event 120 (80.0) 95 (65.5) 0.004
Treatment-related adverse events 85 (56.7) 42 (29.0) <0.001
Serious adverse events 12 (8.0) 8 (5.5) 0.412
Adverse events leading to 8 (5.3) 4 (2.8) 0.257
discontinuation
Deaths 0 (0.0) 1 (0.7) 0.492
Common adverse events (≥5% in any group)
Nausea 45 (30.0) 12 (8.3) <0.001
Diarrhea 38 (25.3) 10 (6.9) <0.001
Headache 22 (14.7) 18 (12.4) 0.568
Hypoglycemia 18 (12.0) 5 (3.4) 0.007
Dizziness 12 (8.0) 8 (5.5) 0.412
──────────────────────────────────────────────────────────────────────────
Adverse events coded using MedDRA version 24.0
```
**Key elements:**
- Overall AE summary
- Serious AEs highlighted
- Deaths reported
- Common AEs (typically ≥5% or ≥10% threshold)
- MedDRA coding indicated
### Laboratory Abnormalities Table
**Shift tables showing changes from baseline:**
```
Table 4. Laboratory Values Meeting Predefined Criteria for Abnormality
Laboratory Parameter Treatment Control
(N=150) (N=145)
n (%) n (%)
──────────────────────────────────────────────────────────────────────────
ALT >3× ULN 8 (5.3) 3 (2.1)
AST >3× ULN 5 (3.3) 2 (1.4)
Total bilirubin >2× ULN 2 (1.3) 1 (0.7)
Creatinine >1.5× baseline 12 (8.0) 5 (3.4)
Hemoglobin <10 g/dL 3 (2.0) 2 (1.4)
Platelets <100 × 10³/μL 1 (0.7) 0 (0.0)
──────────────────────────────────────────────────────────────────────────
ULN = upper limit of normal; ALT = alanine aminotransferase;
AST = aspartate aminotransferase
```
### Patient Disposition Table (CONSORT Format)
```
Table 5. Patient Disposition
Disposition Treatment Control Total
(N=150) (N=145) (N=295)
────────────────────────────────────────────────────────────────────────────
Screened - - 425
Randomized 150 145 295
Completed study 135 (90.0) 130 (89.7) 265 (89.8)
Discontinued, n (%) 15 (10.0) 15 (10.3) 30 (10.2)
Adverse event 8 (5.3) 4 (2.8) 12 (4.1)
Lack of efficacy 2 (1.3) 5 (3.4) 7 (2.4)
Lost to follow-up 3 (2.0) 4 (2.8) 7 (2.4)
Withdrawal of consent 2 (1.3) 2 (1.4) 4 (1.4)
Included in efficacy analysis
ITT population 150 (100) 145 (100) 295 (100)
Per-protocol population 142 (94.7) 138 (95.2) 280 (94.9)
Included in safety analysis 150 (100) 145 (100) 295 (100)
────────────────────────────────────────────────────────────────────────────
ITT = intent-to-treat
```
## Figures for Clinical Data
### Figure Design Principles
**General guidelines:**
- Clear, concise caption/legend below figure
- Numbered sequentially (Figure 1, Figure 2, etc.)
- Axis labels with units
- Legible font size (minimum 8-10 point)
- High resolution (300 dpi for print, 150 dpi for web)
- Color-blind friendly palette
- Black and white compatible (use different symbols/patterns)
**Figure caption:**
- Describes what is shown
- Explains symbols, error bars, statistical annotations
- Defines abbreviations
- Provides context for interpretation
### CONSORT Flow Diagram
**Purpose:** Show patient flow through randomized trial
```
Assessed for eligibility (n=425)
│
┌─────────────────────┴─────────────────────┐
│ │
Excluded (n=130) │
• Not meeting inclusion criteria (n=85) │
• Declined to participate (n=32) │
• Other reasons (n=13) │
│
Randomized (n=295)
│
┌───────────────────────────────┴───────────────────────────────┐
│ │
Allocated to Treatment (n=150) Allocated to Control (n=145)
• Received allocated intervention (n=148) • Received allocated intervention (n=143)
• Did not receive allocated intervention (n=2) • Did not receive allocated intervention (n=2)
Reasons: withdrew consent before treatment Reasons: withdrew consent before treatment
│ │
┌───────────┴────────────┐ ┌──────────────┴─────────────┐
│ │ │ │
Lost to follow-up (n=3) Discontinued (n=12) Lost to follow-up (n=4) Discontinued (n=11)
• Adverse events (n=8) • Adverse events (n=4)
• Lack of efficacy (n=2) • Lack of efficacy (n=5)
• Withdrew consent (n=2) • Withdrew consent (n=2)
│ │
Analyzed (n=150) Analyzed (n=145)
• ITT analysis (n=150) • ITT analysis (n=145)
• Per-protocol analysis (n=142) • Per-protocol analysis (n=138)
• Excluded from analysis (n=0) • Excluded from analysis (n=0)
```
### Kaplan-Meier Survival Curve
**Purpose:** Show time-to-event data
**Elements:**
- X-axis: Time (weeks, months, years)
- Y-axis: Probability of event-free survival (0 to 1 or 0% to 100%)
- Separate curves for each treatment group
- Censored observations marked (often with vertical tick marks)
- Number at risk table below graph
- Median survival time indicated
- Log-rank p-value
- Hazard ratio with 95% CI
**Caption example:**
```
Figure 1. Kaplan-Meier Curves for Overall Survival
Kaplan-Meier estimates of overall survival in the treatment and control groups.
Tick marks indicate censored observations. Number at risk shown below graph.
Log-rank p<0.001. Median survival: Treatment 24.5 months (95% CI: 22.1-26.8),
Control 18.2 months (95% CI: 16.5-20.1). Hazard ratio 0.68 (95% CI: 0.55-0.84).
```
### Forest Plot
**Purpose:** Display subgroup analyses or meta-analysis results
**Elements:**
- Point estimates (squares or diamonds)
- Size of symbol proportional to precision (inverse variance) or sample size
- Horizontal lines showing 95% CI
- Vertical line at null effect (HR=1.0, OR=1.0, or difference=0)
- Subgroup labels on left
- Effect size values on right
- Overall estimate (if meta-analysis)
- Heterogeneity statistics (I², p-value)
**Caption example:**
```
Figure 2. Forest Plot of Treatment Effect by Subgroup
Effect of treatment vs. control on primary endpoint across pre-specified subgroups.
Squares represent point estimates; horizontal lines represent 95% confidence intervals.
Square size is proportional to subgroup sample size. Overall effect shown as diamond.
p-value for interaction testing heterogeneity of treatment effect across subgroups.
```
### Box Plot
**Purpose:** Show distribution of continuous variable
**Elements:**
- Box: IQR (25th to 75th percentile)
- Line in box: Median
- Whiskers: Extend to most extreme data point within 1.5 × IQR
- Outliers: Points beyond whiskers (often shown as circles)
- X-axis: Groups or time points
- Y-axis: Continuous variable with units
### Scatter Plot with Regression
**Purpose:** Show relationship between two continuous variables
**Elements:**
- X-axis: Independent variable
- Y-axis: Dependent variable
- Individual data points
- Regression line (if appropriate)
- Regression equation
- R² value
- P-value for slope
- 95% confidence interval for regression line (optional, shown as shaded area)
### Spaghetti Plot
**Purpose:** Show individual trajectories over time
**Elements:**
- X-axis: Time
- Y-axis: Outcome variable
- Individual patient lines (often semi-transparent)
- Mean trajectory (bold line)
- Separate colors for treatment groups
### Bar Chart
**Purpose:** Compare proportions or means across groups
**Elements:**
- Clear separation between bars
- Error bars (SEM or 95% CI)
- Y-axis starts at 0 (do not truncate for bar charts)
- Group labels on X-axis
- Value labels on Y-axis with units
- Statistical significance indicated (p-values or asterisks)
**Avoid:**
- 3D bar charts (distort perception)
- Excessive decoration
- Truncated Y-axis for bars
### Line Graph
**Purpose:** Show changes over time
**Elements:**
- X-axis: Time (with consistent intervals)
- Y-axis: Outcome variable
- Separate lines for each group (different colors/patterns)
- Data points marked (circles, squares, triangles)
- Error bars at each time point (SE or 95% CI)
- Legend identifying groups
- Grid lines (optional, light gray)
### Histogram
**Purpose:** Show distribution of continuous variable
**Elements:**
- X-axis: Variable (divided into bins)
- Y-axis: Frequency or density
- Appropriate bin width (not too few, not too many)
- Overlay normal distribution curve (if testing normality)
## Special Considerations for Clinical Data
### Presenting Proportions
**Numerator and denominator:**
- Always provide both: 25/100 (25%)
- Not just percentage (25%)
**Percentages:**
- No decimal places if n<100
- 1 decimal place if n≥100
- Never report >1 decimal place for percentages
**Confidence intervals for proportions:**
- Wilson score interval or exact binomial (better than Wald for small samples)
- Always report with percentage
### Presenting Continuous Data
**Measures of central tendency:**
- Mean for normally distributed data
- Median for skewed data or ordinal data
- Report both if distribution unclear
**Measures of dispersion:**
- **Standard deviation (SD)**: Describes variability in data
- **Standard error (SE)**: Describes precision of mean estimate
- **95% Confidence interval**: Preferred for inferential statistics
- **Interquartile range (IQR)**: With median for skewed data
- **Range**: Min to max
**When to use each:**
- Descriptive statistics → Mean (SD) or Median (IQR)
- Inferential statistics → Mean (95% CI) or Mean (SE)
- Never use ± without specifying SD, SE, or CI
### Presenting P-values
**Reporting guidelines:**
- Report exact p-values to 2-3 decimal places (p=0.042)
- For very small p-values, use p<0.001 (not p=0.000)
- Do not report as "NS" or "p=NS"
- For non-significant results, report exact p-value (p=0.18, not p>0.05)
- Specify two-tailed unless pre-specified one-tailed
- Correct for multiple comparisons when appropriate
- Report significance threshold used (α=0.05 is standard)
**Avoid:**
- p<0.05 (report exact value)
- p=0.00 (impossible)
- Multiple decimal places (p=0.04235891)
### Statistical Significance Indicators
**Options:**
1. Report p-values in table
2. Use asterisks with legend:
- *p<0.05
- **p<0.01
- ***p<0.001
3. Use confidence intervals (preferred)
### Confidence Intervals
**Reporting:**
- 95% CI is standard
- Format: (lower limit, upper limit)
- Or: lower limit to upper limit
- Or: lower limit-upper limit
**Interpretation:**
- If CI for difference excludes 0 → significant
- If CI for ratio excludes 1 → significant
- Width of CI indicates precision
### Missing Data
**Indicate clearly:**
- Footnote explaining missing data
- State clearly if analysis is complete case
- Describe imputation method if used
- Report amount of missing data per variable
### Decimal Places and Rounding
**General rules:**
- Report to level of measurement precision
- Consistent decimal places within table
- Round p-values to 2-3 decimal places
- Round percentages to 0-1 decimal place
- Round means/medians to 1-2 decimal places
- Include appropriate significant figures
## Software for Creating Figures
**Statistical software:**
- R (ggplot2) - highly customizable
- GraphPad Prism - user-friendly for biomedical
- SAS, Stata, SPSS - comprehensive statistical packages
- Python (matplotlib, seaborn) - flexible and powerful
**General graphics software:**
- Adobe Illustrator - professional publication-quality
- Inkscape - free vector graphics editor
- PowerPoint - basic graphs, easy to use
- BioRender - biological schematics and figures
## Color Schemes
**Color-blind friendly palettes:**
- Avoid red-green combinations
- Use blue-orange, blue-yellow
- Include shape/pattern differences
- Test figures in grayscale
**Recommended palettes:**
- ColorBrewer (designed for data visualization)
- Viridis (perceptually uniform)
- IBM Color Blind Safe Palette
## Image Quality Standards
**Resolution:**
- 300 dpi for print publication
- 150 dpi for web/screen
- Vector graphics (PDF, SVG) preferred for graphs
**File formats:**
- TIFF or EPS for print
- PNG for web
- PDF for vector graphics
- JPEG acceptable for photographs (high quality)
**Image editing:**
- No manipulation that alters data
- Only acceptable adjustments: brightness, contrast, color balance applied to entire image
- Document all adjustments
- Provide original images if requested
---
This reference provides comprehensive guidance for presenting clinical data in tables and figures following best practices and publication standards. Use these guidelines to create clear, accurate, and professional data presentations.

629
skills/clinical-reports/references/diagnostic_reports_standards.md Normal file
View File

@@ -0,0 +1,629 @@
# Diagnostic Reports Standards
## Radiology Reporting Standards
### American College of Radiology (ACR) Guidelines
The ACR provides comprehensive practice parameters for diagnostic imaging reporting to ensure quality, consistency, and communication effectiveness.
#### Core Radiology Report Components
**1. Patient Demographics**
- Patient name and/or unique identifier
- Date of birth or age
- Sex
- Medical record number
- Examination date and time
- Referring physician
**2. Procedure/Examination**
- Specific examination performed
- Anatomical region
- Laterality (right, left, bilateral)
- Technique and protocol
- Example: "MRI Brain without and with Contrast"
**3. Clinical Indication**
- Reason for examination
- Relevant clinical history
- Specific clinical question
- ICD-10 codes (when required)
- Example: "Headache and visual disturbances. Rule out intracranial mass."
**4. Comparison**
- Prior relevant imaging studies
- Dates of prior studies
- Modality of prior studies
- Availability for comparison
- Example: "Comparison: CT head without contrast from 6 months prior (January 15, 2023)"
**5. Technique**
- Imaging parameters and protocol
- Contrast administration details:
- Type (iodinated, gadolinium)
- Route (IV, oral, rectal)
- Volume administered
- Timing of imaging
- Technical quality statement
- Radiation dose (for CT)
- Limitations or technical issues
- Example:
```
Technique: Multiplanar T1 and T2-weighted sequences were obtained through
the brain without and with IV contrast. 15 mL of gadolinium-based contrast
agent was administered intravenously. Technical quality is adequate.
```
**6. Findings**
- Systematic description of imaging findings
- Organized by anatomical region or organ system
- Measurements of abnormalities (size, volume)
- Specific descriptive terminology
- Pertinent positive findings
- Relevant negative findings
- Comparison to prior studies when available
**Organization approaches:**
- Organ-by-organ (for abdomen/pelvis)
- Region-by-region (for chest)
- System-by-system (for spine)
- Compartment-by-compartment (for musculoskeletal)
**7. Impression/Conclusion**
- Summary of key findings
- Diagnosis or differential diagnosis
- Answers to clinical question
- Level of concern or urgency
- Comparison to prior (improved, stable, worsened)
- Recommendations for further imaging or clinical management
- Clear and concise (often numbered list)
Example:
```
IMPRESSION:
1. 3.2 cm enhancing mass in the right frontal lobe with surrounding vasogenic
edema, most consistent with high-grade glioma. Metastasis cannot be excluded.
Clinical correlation and tissue sampling recommended.
2. No acute intracranial hemorrhage or herniation.
3. Recommend neurosurgical consultation.
```
**8. Critical Results Communication**
- Urgent or unexpected findings requiring immediate action
- Direct communication to ordering provider documented
- Time, date, and recipient of verbal communication
- Example: "Critical result: Acute pulmonary embolism. Dr. Smith paged at 14:35 on [date]."
### Structured Reporting Systems
#### Lung-RADS (Lung CT Screening Reporting and Data System)
Used for lung cancer screening CT interpretation.
**Categories:**
- **Lung-RADS 0**: Incomplete - additional imaging needed
- **Lung-RADS 1**: Negative - no nodules, definitely benign nodules
- **Lung-RADS 2**: Benign appearance or behavior - nodules with very low likelihood of malignancy
- **Lung-RADS 3**: Probably benign - short-interval follow-up suggested
- **Lung-RADS 4A**: Suspicious - 3-month follow-up or PET/CT
- **Lung-RADS 4B**: Very suspicious - 3-month follow-up or PET/CT, consider biopsy
- **Lung-RADS 4X**: Very suspicious with additional features, consider biopsy
**Management recommendations included for each category**
#### BI-RADS (Breast Imaging Reporting and Data System)
Standardized lexicon for breast imaging (mammography, ultrasound, MRI).
**Categories:**
- **BI-RADS 0**: Incomplete - need additional imaging
- **BI-RADS 1**: Negative - no abnormalities
- **BI-RADS 2**: Benign findings
- **BI-RADS 3**: Probably benign - short-interval follow-up (6 months)
- **BI-RADS 4**: Suspicious - biopsy recommended
- 4A: Low suspicion
- 4B: Moderate suspicion
- 4C: High suspicion
- **BI-RADS 5**: Highly suggestive of malignancy - biopsy recommended
- **BI-RADS 6**: Known biopsy-proven malignancy
**Descriptors:**
- Mass: Shape, margin, density
- Calcifications: Morphology, distribution
- Asymmetry: Type and characteristics
- Associated features
#### LI-RADS (Liver Imaging Reporting and Data System)
For reporting liver observations in patients at risk for hepatocellular carcinoma.
**Categories:**
- **LI-RADS 1**: Definitely benign
- **LI-RADS 2**: Probably benign
- **LI-RADS 3**: Intermediate probability of malignancy
- **LI-RADS 4**: Probably HCC
- **LI-RADS 5**: Definitely HCC
- **LI-RADS M**: Probably or definitely malignant, not HCC-specific
- **LI-RADS TIV**: Tumor in vein
**Major features assessed:**
- Size
- Enhancement pattern (arterial phase hyperenhancement, washout)
- Capsule appearance
- Threshold growth
#### PI-RADS (Prostate Imaging Reporting and Data System)
For multiparametric MRI of the prostate.
**Assessment categories:**
- **PI-RADS 1**: Very low - clinically significant cancer highly unlikely
- **PI-RADS 2**: Low - clinically significant cancer unlikely
- **PI-RADS 3**: Intermediate - equivocal
- **PI-RADS 4**: High - clinically significant cancer likely
- **PI-RADS 5**: Very high - clinically significant cancer highly likely
**Evaluation:**
- Peripheral zone: DWI/ADC primary determinant
- Transition zone: T2-weighted primary determinant
- DCE (dynamic contrast-enhanced): Used for PI-RADS 3 lesions in peripheral zone
### RadLex and Standardized Terminology
**RadLex** is a comprehensive lexicon for radiology developed by the Radiological Society of North America (RSNA).
**Benefits:**
- Standardized terminology
- Improved communication
- Enables data mining and analytics
- Facilitates decision support systems
- Consistent report structure
**Common RadLex terms:**
- Anatomical structures
- Imaging observations
- Disease entities
- Procedures
### Radiological Measurements
**Linear measurements:**
- Use bidimensional (length × width) or tridimensional (length × width × height)
- Report largest dimension for nodules/masses
- Consistent measurement methodology for follow-up
- Perpendicular measurements when possible
**Volumetric measurements:**
- More accurate for follow-up of irregular lesions
- Automated or semi-automated software
- Particularly useful for lung nodules
**Response assessment:**
- RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
- Target lesions: sum of longest diameters (maximum 5 lesions, 2 per organ)
- Complete response, partial response, stable disease, progressive disease
## Pathology Reporting Standards
### College of American Pathologists (CAP) Protocols
CAP cancer protocols provide standardized synoptic reporting templates for cancer specimens.
#### Synoptic Reporting Elements
**Core elements for all cancer specimens:**
**1. Specimen Information**
- Procedure type (biopsy, excision, resection)
- Specimen laterality
- Specimen integrity and adequacy
**2. Tumor Site**
- Anatomical site and subsite
- Precise location within organ
**3. Tumor Size**
- Greatest dimension in cm
- Additional dimensions if 3D measurement relevant
- Method of measurement (gross vs. microscopic)
**4. Histologic Type**
- WHO classification
- Specific subtype
- Percentage of each component in mixed tumors
**5. Histologic Grade**
- Grading system used (e.g., Nottingham, Fuhrman, Gleason)
- Grade category (well, moderately, poorly differentiated OR G1, G2, G3)
- Individual component scores if applicable
**6. Extent of Invasion**
- Depth of invasion (measured in mm)
- Involvement of adjacent structures
- Lymphovascular invasion (present/not identified)
- Perineural invasion (present/not identified)
**7. Margins**
- Closest margin distance
- Margin status for each margin assessed (negative/positive)
- Specific margin(s) involved if positive
**8. Lymph Nodes**
- Number of lymph nodes examined
- Number of lymph nodes with metastasis
- Size of largest metastatic deposit
- Extranodal extension (present/absent)
**9. Pathologic Stage (pTNM)**
- pT: Primary tumor extent
- pN: Regional lymph nodes
- pM: Distant metastasis (if known)
- AJCC Cancer Staging Manual edition used
**10. Additional Findings**
- Treatment effect (if post-neoadjuvant therapy)
- Associated lesions (dysplasia, carcinoma in situ)
- Background tissue (cirrhosis, inflammation)
**11. Ancillary Studies**
- Immunohistochemistry results
- Molecular/genetic testing results
- Biomarker status (e.g., ER, PR, HER2 for breast; MSI for colon)
- FISH or other cytogenetic results
#### Organ-Specific CAP Protocols
**Breast Cancer:**
- Histologic type (invasive ductal, lobular, special types)
- Nottingham grade (tubule formation, nuclear pleomorphism, mitotic count)
- ER/PR status (percentage and intensity)
- HER2 status (IHC score, FISH if needed)
- Ki-67 proliferation index
- DCIS component (if present)
- Response to neoadjuvant therapy (residual cancer burden)
**Colorectal Cancer:**
- Histologic type (adenocarcinoma, mucinous, etc.)
- Grade
- Depth of invasion (into submucosa, muscularis propria, pericolic tissue, etc.)
- Tumor deposits
- Lymph nodes (number positive/total examined)
- Margins (proximal, distal, radial/circumferential)
- MSI/MMR status
- KRAS, NRAS, BRAF mutations
**Prostate Cancer:**
- Gleason score (primary + secondary pattern)
- Grade group (1-5)
- Percentage of tissue involved
- Extraprostatic extension
- Seminal vesicle invasion
- Surgical margin status
- Lymph nodes if sampled
**Lung Cancer:**
- Histologic type (adenocarcinoma, squamous, small cell, etc.)
- Grade (for NSCLC)
- Invasion depth
- Visceral pleural invasion
- Distance to margins
- Lymph nodes
- Molecular markers (EGFR, ALK, ROS1, PD-L1)
### Gross Pathology Description
**Essential elements:**
- Specimen labeling and identification
- Type of specimen
- Dimensions and weight
- Orientation markers (if present)
- External surface description
- Cut surface appearance
- Lesion description:
- Size (3 dimensions)
- Location
- Color
- Consistency
- Borders (well-circumscribed, infiltrative)
- Distance to margins
- Sampling approach (how tissue was sectioned and submitted)
**Example:**
```
GROSS DESCRIPTION:
Received fresh, labeled with patient name and "left breast, lumpectomy" is an
oriented lumpectomy specimen measuring 8.5 x 6.0 x 4.0 cm, with a suture
indicating superior margin. Inking: superior - blue, inferior - black, medial -
green, lateral - red, anterior - orange, posterior - yellow. Serially sectioned
to reveal a firm, gray-white mass measuring 2.1 x 1.8 x 1.5 cm, located 2.5 cm
from superior, 3.0 cm from inferior, 2.0 cm from medial, 3.5 cm from lateral,
1.5 cm from anterior, and 1.8 cm from posterior margins. Representative sections
submitted as follows: A1-A3 tumor, A4 superior margin, A5 medial margin, A6
posterior margin.
```
### Microscopic Description
**Key elements:**
- Architectural pattern
- Cellular characteristics
- Cell type
- Nuclear features (size, shape, chromatin, nucleoli)
- Cytoplasmic features
- Mitotic activity
- Degree of differentiation
- Invasion pattern
- Special features (necrosis, hemorrhage, calcification)
- Stroma and background tissue
- Lymphovascular or perineural invasion
- Margins (distance and status)
- Lymph nodes (description of metastases)
### Frozen Section Reporting
**Indications:**
- Intraoperative diagnosis
- Margin assessment
- Lymph node evaluation
- Tissue triage
**Report format:**
- "Frozen section diagnosis" clearly labeled
- Intraoperative consultation note
- Time of frozen section
- Specimen description
- Frozen section diagnosis
- Note: "Permanent sections to follow"
**Frozen section disclaimers:**
- Limited by frozen artifact
- Final diagnosis on permanent sections
- Defer to permanent sections for definitive diagnosis
### Diagnostic Certainty Language
**Definitive:**
- "Consistent with..."
- "Diagnostic of..."
- "Positive for..."
**Probable:**
- "Consistent with..."
- "Favor..."
- "Most likely..."
**Possible:**
- "Suggestive of..."
- "Cannot exclude..."
- "Differential diagnosis includes..."
**Defer:**
- "Defer to..."
- "Recommend..."
- "Additional studies pending..."
## Laboratory Reporting Standards
### Clinical Laboratory Standards Institute (CLSI) Guidelines
CLSI provides standards for laboratory testing and reporting.
#### Laboratory Report Components
**1. Patient Demographics**
- Patient name and identifier
- Date of birth or age
- Sex
- Ordering provider
**2. Specimen Information**
- Specimen type (blood, serum, plasma, urine, CSF, etc.)
- Collection date and time
- Received date and time
- Specimen condition
- Fasting status (if relevant)
**3. Test Information**
- Test name (full, not just abbreviation)
- Test code
- Methodology
- Accession or specimen number
**4. Results**
- Quantitative value with units
- Qualitative result (positive/negative, detected/not detected)
- Reference range or interval
- Flags for abnormal results
- H = High
- L = Low
- Critical or panic values highlighted
**5. Reference Intervals**
- Age-specific
- Sex-specific
- Population-specific (when relevant)
- Method-specific
- Units clearly stated
**Example:**
```
Test: Hemoglobin A1c
Result: 8.2% (H)
Reference Range: 4.0-5.6% (non-diabetic)
Method: HPLC
Interpretation: Consistent with poorly controlled diabetes
```
**6. Interpretative Comments**
- When result requires context
- Suggests additional testing
- Explains interferences or limitations
- Provides clinical guidance
**7. Quality Control**
- Delta checks (comparison to prior values)
- Critical values and read-back procedure
- Specimen quality issues (hemolysis, lipemia, icterus)
- Dilutions performed
- Repeat testing if needed
### LOINC (Logical Observation Identifiers Names and Codes)
Standard coding system for laboratory and clinical observations.
**LOINC code components:**
- Component (analyte measured)
- Property (mass, substance concentration, etc.)
- Timing (point in time, 24-hour)
- System (specimen type)
- Scale (quantitative, ordinal, nominal)
- Method (when relevant)
**Example:**
- Hemoglobin A1c in Blood: 4548-4
- Glucose in Serum/Plasma: 2345-7
- Creatinine in Serum/Plasma: 2160-0
### Critical Value Reporting
**Definition:** Results that indicate life-threatening conditions requiring immediate clinical action.
**Critical value examples:**
- Glucose: <40 mg/dL or >500 mg/dL
- Potassium: <2.5 mEq/L or >6.5 mEq/L
- Sodium: <120 mEq/L or >160 mEq/L
- Calcium: <6.0 mg/dL or >13.0 mg/dL
- WBC: <1.0 × 10³/μL or >50 × 10³/μL
- Hemoglobin: <5.0 g/dL
- Platelets: <20 × 10³/μL
- INR: >5.0 (on warfarin)
- Positive blood culture
- Positive CSF culture or gram stain
**Critical value procedure:**
1. Result identified by laboratory
2. Immediate contact with ordering provider or designee
3. Read-back verification
4. Documentation:
- Date and time
- Person contacted
- Person receiving notification
- Test and result
5. Follow facility policy for unable to reach provider
### Microbiology Reporting
**Culture reports:**
- Specimen type and source
- Organisms identified
- Quantity (light, moderate, heavy growth)
- Antimicrobial susceptibility results
- Interpretation (susceptible, intermediate, resistant)
- MIC values when applicable
**Gram stain reports:**
- Bacteria present (Gram-positive/negative, morphology)
- Quantity and cellular context
- WBCs or other cells present
**Preliminary reports:**
- Issued before final identification
- Clearly labeled "PRELIMINARY"
- Final report to follow
**Final reports:**
- Definitive organism identification
- Complete susceptibility panel
- Interpretative comments
### Molecular Pathology/Genomics Reporting
**Components:**
- Gene(s) tested
- Variant(s) detected
- Classification (pathogenic, likely pathogenic, VUS, likely benign, benign)
- Allele frequency
- Methodology (NGS, Sanger sequencing, PCR, etc.)
- Reference sequence
- Clinical significance and interpretation
- Recommendations (treatment implications, family testing)
- Limitations of testing
**Example:**
```
Test: BRCA1/BRCA2 Full Gene Sequencing
Result: PATHOGENIC VARIANT DETECTED
Gene: BRCA1
Variant: c.68_69delAG (p.Glu23ValfsTer17)
Classification: Pathogenic
Interpretation: This variant is associated with increased risk of breast and
ovarian cancer. Genetic counseling and risk-reducing strategies recommended.
Family testing should be considered.
```
### Point-of-Care Testing (POCT)
**Requirements:**
- Same quality standards as central laboratory
- Operator competency documentation
- Quality control documentation
- Maintenance records
- Result documentation in medical record
**Common POCT:**
- Blood glucose
- Hemoglobin/hematocrit
- INR
- Blood gas
- Pregnancy test
- Urinalysis
- Rapid strep
- Influenza
## Quality Indicators for Diagnostic Reports
### Radiology Quality Metrics
- Report turnaround time (routine vs. urgent)
- Critical result communication time
- Report error rates
- Addendum rate
- Referring physician satisfaction
**Benchmarks:**
- Routine reports: <24 hours
- Urgent reports: <4 hours
- STAT reports: <1 hour
- Critical findings: Immediate verbal communication
### Pathology Quality Metrics
- Turnaround time (TAT) for different specimen types
- Frozen section accuracy
- Amendment rate
- Specimen adequacy rate
- Immunohistochemistry QC
**TAT benchmarks:**
- Surgical pathology routine: 2-3 days
- Surgical pathology complex: 5-7 days
- Cytology: 1-2 days
- Frozen section: 15-20 minutes intraoperatively
### Laboratory Quality Metrics
- TAT from collection to result
- Critical value notification time
- Specimen rejection rate
- Proficiency testing performance
- Delta check failure rate
**TAT benchmarks:**
- STAT laboratory: <60 minutes
- Routine laboratory: 2-4 hours
- Send-out tests: Per reference laboratory
---
This reference provides comprehensive standards for diagnostic reporting across radiology, pathology, and laboratory medicine. Refer to these guidelines to ensure reports meet professional standards and regulatory requirements.

588
skills/clinical-reports/references/medical_terminology.md Normal file
View File

@@ -0,0 +1,588 @@
# Medical Terminology and Coding Standards
## Standard Nomenclature Systems
### SNOMED CT (Systematized Nomenclature of Medicine - Clinical Terms)
**Purpose:** Comprehensive clinical terminology for electronic health records
**Coverage:**
- Clinical findings
- Symptoms
- Diagnoses
- Procedures
- Body structures
- Organisms
- Substances
- Pharmaceutical products
- Specimens
**Structure:**
- Concepts with unique identifiers
- Descriptions (preferred and synonyms)
- Relationships between concepts
- Hierarchical organization
**Example:**
- Concept: Myocardial infarction
- SNOMED CT code: 22298006
- Parent: Heart disease
- Children: Acute myocardial infarction, Old myocardial infarction
**Benefits:**
- Enables semantic interoperability
- Supports clinical decision support
- Facilitates data analytics
- International standard
### LOINC (Logical Observation Identifiers Names and Codes)
**Purpose:** Universal code system for laboratory and clinical observations
**Components of LOINC code:**
1. **Component** (analyte or measurement): What is measured
2. **Property**: What characteristic (mass, volume, etc.)
3. **Timing**: When measured (point in time, 24-hour)
4. **System**: Specimen or system (serum, urine, arterial blood)
5. **Scale**: Type of result (quantitative, ordinal, nominal)
6. **Method**: How measured (when relevant to interpretation)
**Examples:**
- **Glucose [Mass/volume] in Serum or Plasma**: 2345-7
- Component: Glucose
- Property: Mass concentration
- Timing: Point in time
- System: Serum/Plasma
- Scale: Quantitative
- **Hemoglobin A1c/Hemoglobin.total in Blood**: 4548-4
- Component: Hemoglobin A1c/Hemoglobin.total
- Property: Mass fraction
- Timing: Point in time
- System: Blood
- Scale: Quantitative
**LOINC Parts:**
- Document types
- Survey instruments
- Clinical attachments
- Radiology codes
- Pathology codes
### ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification)
**Purpose:** Diagnosis and procedure coding for billing, epidemiology, and health statistics
**Structure:**
- Alphanumeric codes (3-7 characters)
- First character: letter (except U)
- Characters 2-3: numbers
- Characters 4-7: alphanumeric (decimal after 3rd character)
- Laterality, severity, encounter type specified
**Code structure example:**
- **S72.001A**: Fracture of unspecified part of neck of right femur, initial encounter
- S: Injury category
- 72: Femur
- 001: Unspecified part of neck
- A: Initial encounter for closed fracture
- Right side indicated by 1 in 5th position
**Common categories:**
- A00-B99: Infectious diseases
- C00-D49: Neoplasms
- E00-E89: Endocrine, nutritional, metabolic
- F01-F99: Mental and behavioral
- G00-G99: Nervous system
- I00-I99: Circulatory system
- J00-J99: Respiratory system
- K00-K95: Digestive system
- M00-M99: Musculoskeletal
- N00-N99: Genitourinary
- S00-T88: Injury, poisoning
**Seventh character extensions:**
- A: Initial encounter
- D: Subsequent encounter
- S: Sequela
**Placeholder X:**
- Used when code requires 7th character but fewer than 6 characters
- Example: T36.0X5A (Adverse effect of penicillins, initial encounter)
**Combination codes:**
- Single code describing two diagnoses or diagnosis with manifestation
- Example: E11.21 (Type 2 diabetes with diabetic nephropathy)
### CPT (Current Procedural Terminology)
**Purpose:** Procedure and service coding for billing
**Maintained by:** American Medical Association (AMA)
**Categories:**
- **Category I**: Procedures and services (5-digit numeric codes)
- **Category II**: Performance measurement (4 digits + F)
- **Category III**: Emerging technology (4 digits + T)
**Category I Sections:**
- 00100-01999: Anesthesia
- 10000-69990: Surgery
- 70000-79999: Radiology
- 80000-89999: Pathology and Laboratory
- 90000-99999: Medicine
- 99000-99607: Evaluation and Management (E/M)
**E/M Codes (commonly used):**
- **99201-99215**: Office visits (new and established)
- **99221-99239**: Hospital inpatient services
- **99281-99285**: Emergency department visits
- **99291-99292**: Critical care
- **99304-99318**: Nursing facility services
**Modifiers:**
- Two-digit codes appended to CPT codes
- Indicate service was altered but not changed
- Examples:
- -25: Significant, separately identifiable E/M service
- -50: Bilateral procedure
- -59: Distinct procedural service
- -76: Repeat procedure by same physician
- -RT/LT: Right/Left side
### RxNorm
**Purpose:** Normalized names for clinical drugs and drug delivery devices
**Structure:**
- Includes brand and generic names
- Dose forms
- Strengths
- Links to other drug vocabularies (NDC, SNOMED CT)
**Example:**
- Concept: Amoxicillin 500 MG Oral Capsule
- RxNorm CUI: 308191
- Ingredients: Amoxicillin
- Strength: 500 MG
- Dose Form: Oral Capsule
## Medical Abbreviations
### Acceptable Standard Abbreviations
**Time:**
- q: every (q4h = every 4 hours)
- qd: daily (avoid - use "daily")
- bid: twice daily
- tid: three times daily
- qid: four times daily
- qhs: at bedtime
- prn: as needed
- ac: before meals
- pc: after meals
- hs: at bedtime
**Routes:**
- PO: by mouth (per os)
- IV: intravenous
- IM: intramuscular
- SC/SQ/subcut: subcutaneous
- SL: sublingual
- PR: per rectum
- NG: nasogastric
- GT: gastrostomy tube
- TD: transdermal
- inh: inhaled
**Frequency:**
- stat: immediately
- now: immediately
- continuous: without interruption
- PRN: as needed
**Laboratory:**
- CBC: complete blood count
- BMP: basic metabolic panel
- CMP: comprehensive metabolic panel
- LFTs: liver function tests
- PT/INR: prothrombin time/international normalized ratio
- PTT/aPTT: partial thromboplastin time/activated PTT
- ESR: erythrocyte sedimentation rate
- CRP: C-reactive protein
- ABG: arterial blood gas
- UA: urinalysis
- HbA1c: hemoglobin A1c
**Diagnoses:**
- HTN: hypertension
- DM: diabetes mellitus
- CHF: congestive heart failure
- CAD: coronary artery disease
- COPD: chronic obstructive pulmonary disease
- CVA: cerebrovascular accident
- MI: myocardial infarction
- PE: pulmonary embolism
- DVT: deep vein thrombosis
- UTI: urinary tract infection
- CKD: chronic kidney disease
- ESRD: end-stage renal disease
**Physical Examination:**
- HEENT: head, eyes, ears, nose, throat
- PERRLA: pupils equal, round, reactive to light and accommodation
- EOMI: extraocular movements intact
- JVP: jugular venous pressure
- RRR: regular rate and rhythm
- CTAB: clear to auscultation bilaterally
- BS: bowel sounds or breath sounds (context dependent)
- NT/ND: non-tender, non-distended
- FROM: full range of motion
**Vital Signs:**
- BP: blood pressure
- HR: heart rate
- RR: respiratory rate
- T or Temp: temperature
- SpO2: oxygen saturation
- Wt: weight
- Ht: height
- BMI: body mass index
### Do Not Use Abbreviations (Joint Commission)
**Prohibited abbreviations:**
| Abbreviation | Intended Meaning | Problem | Use Instead |
|--------------|------------------|---------|-------------|
| U | Unit | Mistaken for 0, 4, or cc | Write "unit" |
| IU | International Unit | Mistaken for IV or 10 | Write "international unit" |
| Q.D., QD, q.d., qd | Daily | Mistaken for each other | Write "daily" |
| Q.O.D., QOD, q.o.d., qod | Every other day | Mistaken for QD or QID | Write "every other day" |
| Trailing zero (X.0 mg) | X mg | Decimal point missed | Never write zero after decimal (write X mg) |
| Lack of leading zero (.X mg) | 0.X mg | Decimal point missed | Always write zero before decimal (write 0.X mg) |
| MS, MSO4, MgSO4 | Morphine sulfate or magnesium sulfate | Confused for each other | Write "morphine sulfate" or "magnesium sulfate" |
**Additional problematic abbreviations:**
- µg: micrograms (mistaken for mg) → write "mcg"
- cc: cubic centimeters → write "mL"
- hs: half-strength or hour of sleep → write "half-strength" or "bedtime"
- TIW: three times a week → write "three times weekly"
- SC, SQ: subcutaneous → write "subcut" or "subcutaneous"
- D/C: discharge or discontinue → write full word
- AS, AD, AU: left ear, right ear, both ears → write "left ear," "right ear," "both ears"
- OS, OD, OU: left eye, right eye, both eyes → write "left eye," "right eye," "both eyes"
## Medication Nomenclature
### Generic vs. Brand Names
**Best practice:** Use generic names in medical documentation
**Examples:**
- Acetaminophen (generic) vs. Tylenol (brand)
- Ibuprofen (generic) vs. Advil, Motrin (brand)
- Atorvastatin (generic) vs. Lipitor (brand)
- Metformin (generic) vs. Glucophage (brand)
- Lisinopril (generic) vs. Zestril, Prinivil (brand)
**When to include brand:**
- Patient education (recognition)
- Novel drugs without generic
- Narrow therapeutic index drugs with bioequivalence issues
- Biologic products
### Dosage Forms
**Solid oral:**
- Tablet
- Capsule
- Caplet
- Chewable tablet
- Orally disintegrating tablet (ODT)
- Extended-release (ER, XR, SR)
- Delayed-release (DR)
**Liquid oral:**
- Solution
- Suspension
- Syrup
- Elixir
- Drops
**Parenteral:**
- Solution for injection
- Powder for injection (reconstituted)
- Intravenous infusion
- Intramuscular injection
- Subcutaneous injection
**Topical:**
- Cream
- Ointment
- Gel
- Lotion
- Paste
- Patch (transdermal)
- Foam
- Spray
**Other:**
- Suppository (rectal, vaginal)
- Inhaler (MDI, DPI)
- Nebulizer solution
- Ophthalmic (drops, ointment)
- Otic (drops)
- Nasal spray
### Prescription Writing Elements
**Complete prescription includes:**
1. Patient name and DOB
2. Date
3. Medication name (generic preferred)
4. Strength/concentration
5. Dosage form
6. Quantity to dispense
7. Directions (Sig)
8. Number of refills
9. Prescriber signature and credentials
10. DEA number (for controlled substances)
**Sig (Directions for use):**
- Clear, specific instructions
- Route of administration
- Frequency
- Duration (if applicable)
- Special instructions
**Example:**
- "Take one tablet by mouth twice daily with food for 10 days"
- "Apply thin layer to affected area three times daily"
- "Instill 1 drop in each eye every 4 hours while awake"
## Anatomical Terminology
### Directional Terms
**Superior/Inferior:**
- Superior: toward the head
- Inferior: toward the feet
- Cranial: toward the head
- Caudal: toward the tail/feet
**Anterior/Posterior:**
- Anterior: toward the front
- Posterior: toward the back
- Ventral: toward the belly
- Dorsal: toward the back
**Medial/Lateral:**
- Medial: toward the midline
- Lateral: away from the midline
**Proximal/Distal:**
- Proximal: closer to the trunk or point of origin
- Distal: farther from the trunk or point of origin
**Superficial/Deep:**
- Superficial: toward the surface
- Deep: away from the surface
### Body Planes
**Sagittal plane:** Divides body into right and left
- Midsagittal: exactly through midline
- Parasagittal: parallel to midline
**Coronal (frontal) plane:** Divides body into anterior and posterior
**Transverse (axial) plane:** Divides body into superior and inferior
### Anatomical Position
- Standing upright
- Feet parallel
- Arms at sides
- Palms facing forward
- Head facing forward
### Regional Terms
**Head and Neck:**
- Cephalic: head
- Frontal: forehead
- Orbital: eye
- Nasal: nose
- Oral: mouth
- Cervical: neck
- Occipital: back of head
**Trunk:**
- Thoracic: chest
- Abdominal: abdomen
- Pelvic: pelvis
- Lumbar: lower back
- Sacral: sacrum
**Extremities:**
- Brachial: arm
- Antebrachial: forearm
- Carpal: wrist
- Manual: hand
- Digital: fingers/toes
- Femoral: thigh
- Crural: leg
- Tarsal: ankle
- Pedal: foot
## Laboratory Units and Conversions
### Common Laboratory Units
**Hematology:**
- RBC: × 10⁶/μL or × 10¹²/L
- WBC: × 10³/μL or × 10⁹/L
- Hemoglobin: g/dL or g/L
- Hematocrit: % or fraction
- Platelets: × 10³/μL or × 10⁹/L
- MCV: fL
- MCHC: g/dL or g/L
**Chemistry:**
- Glucose: mg/dL or mmol/L
- BUN: mg/dL or mmol/L
- Creatinine: mg/dL or μmol/L
- Sodium, potassium, chloride: mEq/L or mmol/L
- Calcium: mg/dL or mmol/L
- Albumin: g/dL or g/L
- Bilirubin: mg/dL or μmol/L
- Cholesterol: mg/dL or mmol/L
**Therapeutic Drug Levels:**
- Usually: mcg/mL, ng/mL, or μmol/L
### Unit Conversions (Selected)
**Glucose:**
- mg/dL ÷ 18 = mmol/L
- mmol/L × 18 = mg/dL
**Creatinine:**
- mg/dL × 88.4 = μmol/L
- μmol/L ÷ 88.4 = mg/dL
**Bilirubin:**
- mg/dL × 17.1 = μmol/L
- μmol/L ÷ 17.1 = mg/dL
**Cholesterol:**
- mg/dL × 0.0259 = mmol/L
- mmol/L × 38.67 = mg/dL
**Hemoglobin:**
- g/dL × 10 = g/L
- g/L ÷ 10 = g/dL
## Grading and Staging Systems
### Cancer Staging (TNM)
**T (Primary Tumor):**
- TX: Cannot be assessed
- T0: No evidence of primary tumor
- Tis: Carcinoma in situ
- T1-T4: Size and/or extent of primary tumor
**N (Regional Lymph Nodes):**
- NX: Cannot be assessed
- N0: No regional lymph node metastasis
- N1-N3: Involvement of regional lymph nodes
**M (Distant Metastasis):**
- M0: No distant metastasis
- M1: Distant metastasis present
**Stage Grouping:**
- Stage 0: Tis N0 M0
- Stage I-III: Various T and N combinations, M0
- Stage IV: Any T, any N, M1
### NYHA Heart Failure Classification
- **Class I**: No limitation. Ordinary physical activity does not cause symptoms
- **Class II**: Slight limitation. Comfortable at rest, ordinary activity causes symptoms
- **Class III**: Marked limitation. Comfortable at rest, less than ordinary activity causes symptoms
- **Class IV**: Unable to carry out any physical activity without symptoms. Symptoms at rest
### Child-Pugh Score (Liver Disease)
**Parameters:** Bilirubin, albumin, INR, ascites, encephalopathy
**Classes:**
- **Class A (5-6 points)**: Well-compensated
- **Class B (7-9 points)**: Significant functional compromise
- **Class C (10-15 points)**: Decompensated
### Glasgow Coma Scale
**Eye Opening (1-4):**
- 4: Spontaneous
- 3: To speech
- 2: To pain
- 1: None
**Verbal Response (1-5):**
- 5: Oriented
- 4: Confused
- 3: Inappropriate words
- 2: Incomprehensible sounds
- 1: None
**Motor Response (1-6):**
- 6: Obeys commands
- 5: Localizes pain
- 4: Withdraws from pain
- 3: Abnormal flexion
- 2: Extension
- 1: None
**Total Score:** 3-15 (3 = worst, 15 = best)
- Severe: ≤8
- Moderate: 9-12
- Mild: 13-15
## Medical Prefixes and Suffixes
### Common Prefixes
- **a-/an-**: without, absence (anemia, aphasia)
- **brady-**: slow (bradycardia)
- **dys-**: abnormal, difficult (dyspnea, dysuria)
- **hyper-**: excessive, above (hypertension, hyperglycemia)
- **hypo-**: below, deficient (hypotension, hypoglycemia)
- **poly-**: many (polyuria, polydipsia)
- **tachy-**: fast (tachycardia, tachypnea)
- **macro-**: large (macrocephaly)
- **micro-**: small (microcephaly)
- **hemi-**: half (hemiplegia)
- **bi-/di-**: two (bilateral, diplopia)
### Common Suffixes
- **-algia**: pain (arthralgia, neuralgia)
- **-ectomy**: surgical removal (appendectomy, cholecystectomy)
- **-emia**: blood condition (anemia, leukemia)
- **-itis**: inflammation (appendicitis, arthritis)
- **-oma**: tumor (carcinoma, melanoma)
- **-osis**: abnormal condition (cirrhosis, osteoporosis)
- **-pathy**: disease (neuropathy, nephropathy)
- **-penia**: deficiency (thrombocytopenia, neutropenia)
- **-plasty**: surgical repair (rhinoplasty, angioplasty)
- **-scopy**: visual examination (colonoscopy, bronchoscopy)
- **-stomy**: surgical opening (colostomy, tracheostomy)
---
This reference provides comprehensive medical terminology, coding systems, abbreviations, and nomenclature standards. Use these guidelines to ensure accurate, standardized clinical documentation.

744
skills/clinical-reports/references/patient_documentation.md Normal file
View File

@@ -0,0 +1,744 @@
# Patient Documentation Standards
## SOAP Notes
SOAP (Subjective, Objective, Assessment, Plan) is the standard format for progress notes in clinical practice.
### Purpose and Use
**When to use SOAP notes:**
- Daily progress notes in hospital
- Outpatient visit documentation
- Subspecialty consultations
- Follow-up visits
- Documenting response to treatment
**Benefits:**
- Standardized structure
- Organized clinical reasoning
- Facilitates communication
- Supports billing and coding
- Legal documentation
### SOAP Components
#### S - Subjective
**Definition:** Information reported by the patient (symptoms, concerns, history)
**Elements to include:**
- Chief complaint or reason for visit
- History of present illness (HPI)
- Review of systems (ROS) relevant to visit
- Patient's description of symptoms
- Response to prior treatments
- Functional impact
- Patient concerns or questions
**HPI Elements (use OPQRST for pain/symptoms):**
- **O**nset: When did it start? Sudden or gradual?
- **P**rovocation/Palliation: What makes it better or worse?
- **Q**uality: What does it feel like? (sharp, dull, burning, etc.)
- **R**egion/Radiation: Where is it? Does it spread?
- **S**everity: How bad is it? (0-10 scale)
- **T**iming: Constant or intermittent? Duration? Frequency?
**Associated symptoms:**
- Other symptoms occurring with primary complaint
- Pertinent negatives (absence of expected symptoms)
**Response to treatment:**
- Medications taken and effect
- Prior interventions and outcomes
- Compliance with treatment plan
**Example Subjective section:**
```
S: Patient reports persistent cough for 5 days, productive of yellow sputum. Associated
with fever to 101.5°F, measured at home yesterday. Denies shortness of breath, chest
pain, or hemoptysis. Started on azithromycin 2 days ago by urgent care, with minimal
improvement. Reports decreased appetite but able to maintain hydration. Denies recent
travel or sick contacts.
```
#### O - Objective
**Definition:** Measurable, observable clinical data
**Elements to include:**
**Vital Signs:**
- Temperature (°F or °C)
- Blood pressure (mmHg)
- Heart rate (bpm)
- Respiratory rate (breaths/min)
- Oxygen saturation (%)
- Height and weight (calculate BMI)
- Pain score if applicable
**General Appearance:**
- Overall appearance (well, ill, distressed)
- Age appropriateness
- Nutritional status
- Hygiene
- Affect and behavior
**Physical Examination by System:**
- Organized head-to-toe or by systems
- Relevant findings for presenting complaint
- Include pertinent positives and negatives
**Standard examination systems:**
1. **HEENT** (Head, Eyes, Ears, Nose, Throat)
2. **Neck** (thyroid, lymph nodes, JVD, carotids)
3. **Cardiovascular** (heart sounds, murmurs, peripheral pulses, edema)
4. **Pulmonary/Respiratory** (breath sounds, work of breathing)
5. **Abdomen** (bowel sounds, tenderness, organomegaly, masses)
6. **Extremities** (edema, pulses, ROM, deformities)
7. **Neurological** (mental status, cranial nerves, motor, sensory, reflexes, gait)
8. **Skin** (rashes, lesions, wounds)
9. **Psychiatric** (mood, affect, thought process/content)
**Laboratory and Imaging Results:**
- Relevant test results
- Include reference ranges for abnormal values
- Note timing of tests relative to visit
**Example Objective section:**
```
O: Vitals: T 100.8°F, BP 128/82, HR 92, RR 18, SpO2 96% on room air
General: Alert, mild respiratory distress, appears mildly ill
HEENT: Oropharynx without erythema or exudates, TMs clear bilaterally
Neck: No lymphadenopathy, no JVD
Cardiovascular: Regular rate and rhythm, no murmurs
Pulmonary: Decreased breath sounds right lower lobe, dullness to percussion, egophony
present. No wheezes.
Abdomen: Soft, non-tender, no organomegaly
Extremities: No edema, pulses 2+ bilaterally
Neurological: Alert and oriented x3, no focal deficits
Labs (drawn today):
WBC 14.2 x10³/μL (H) [ref 4.5-11.0]
Hemoglobin 13.5 g/dL
Platelets 245 x10³/μL
CRP 8.5 mg/dL (H) [ref <0.5]
Chest X-ray: Right lower lobe consolidation consistent with pneumonia
```
#### A - Assessment
**Definition:** Clinical impression, diagnosis, and evaluation of patient status
**Elements to include:**
- Primary diagnosis or problem
- Secondary diagnoses or problems
- Differential diagnosis if uncertain
- Severity assessment
- Progress toward treatment goals
- Complications or new problems
**Format:**
- Problem list (numbered)
- Each problem with brief assessment
- Include ICD-10 codes when appropriate for billing
**Example Assessment section:**
```
A:
1. Community-acquired pneumonia (CAP), right lower lobe (J18.1)
- Moderate severity (CURB-65 score 1)
- Appropriate for outpatient management
- Minimal improvement on azithromycin, likely bacterial etiology
2. Dehydration, mild (E86.0)
- Secondary to decreased PO intake
3. Type 2 diabetes mellitus (E11.9)
- Well-controlled, continue home medications
```
#### P - Plan
**Definition:** Diagnostic and therapeutic interventions
**Elements to include:**
- Diagnostic plan (further testing, imaging, referrals)
- Therapeutic plan (medications, procedures, therapies)
- Patient education and counseling
- Follow-up arrangements
- Specific instructions for patient
- Return precautions (when to seek urgent care)
**Medication documentation:**
- Drug name (generic preferred)
- Dose and route
- Frequency
- Duration
- Indication
**Plan organization:**
- By problem (matches assessment)
- By intervention type (diagnostics, therapeutics, education)
**Example Plan section:**
```
P:
1. Community-acquired pneumonia:
Diagnostics: None additional at this time
Therapeutics:
- Discontinue azithromycin
- Start amoxicillin-clavulanate 875/125 mg PO BID x 7 days
- Supportive care: adequate hydration, rest, acetaminophen for fever
Education:
- Explained bacterial pneumonia diagnosis and antibiotic change
- Discussed expected improvement within 48-72 hours
- Return precautions: worsening dyspnea, high fever >103°F, confusion
Follow-up: Phone call in 48 hours to assess response, clinic visit in 1 week
2. Dehydration:
- Encourage PO fluids, goal 2 liters/day
- Sports drinks or electrolyte solutions acceptable
3. Type 2 diabetes:
- Continue metformin 1000 mg PO BID
- Home glucose monitoring
- Follow-up with endocrinology as scheduled
Patient verbalized understanding and agreement with plan.
```
### SOAP Note Best Practices
**Documentation standards:**
- Write legibly if handwritten
- Use standard abbreviations only
- Date and time each entry
- Sign and credential all entries
- Document in real-time or as soon as possible
- Avoid copy-forward errors
- Review and update problem list
**Billing considerations:**
- Document medical necessity
- Match documentation to billing level
- Include required elements for E/M coding
- Document time for time-based billing
**Legal considerations:**
- Document facts, not opinions or judgment
- Quote patient when relevant
- Document non-compliance objectively
- Never alter records
- Use addendums for corrections
## History and Physical (H&P)
### Purpose
- Comprehensive baseline assessment
- Document patient status at admission or initial encounter
- Guide diagnosis and treatment planning
- Required within 24 hours of admission (TJC requirement)
### H&P Components
#### Header Information
- Patient name, DOB, MRN
- Date and time of examination
- Admitting diagnosis
- Attending physician
- Service
- Location (ED, floor, ICU)
#### Chief Complaint (CC)
**Definition:** Brief statement of why patient is seeking care
**Format:**
- One sentence
- Use patient's own words (in quotes)
- Example: CC: "I can't catch my breath"
#### History of Present Illness (HPI)
**Purpose:** Detailed chronological narrative of current problem
**Required elements (for billing):**
- Location
- Quality
- Severity
- Duration
- Timing
- Context
- Modifying factors
- Associated signs/symptoms
**Structure:**
- Opening statement (demographics, presenting problem)
- Chronological description
- Symptom characterization
- Prior workup or treatment
- What prompted presentation now
**Example:**
```
HPI: Mr. Smith is a 65-year-old man with history of CHF (EF 35%) who presents with
3 days of progressive dyspnea on exertion. Patient reports dyspnea now occurs with
walking 10 feet (baseline 1-2 blocks). Associated with orthopnea (now requiring
3 pillows, baseline 1) and lower extremity swelling. Denies chest pain, palpitations,
or syncope. Reports medication compliance but notes running out of furosemide 2 days
ago. Weight increased 8 lbs over past week. Has not been monitoring daily weights
at home. Presented to ED today when dyspnea worsened and developed while at rest.
```
#### Past Medical History (PMH)
**Include:**
- Chronic medical conditions
- Previous hospitalizations
- Major illnesses
- Injuries
- Childhood illnesses (if relevant)
**Format:**
```
PMH:
1. Heart failure with reduced ejection fraction (2018), EF 35% on echo 6 months ago
2. Coronary artery disease, s/p CABG (2019)
3. Type 2 diabetes mellitus (2010)
4. Hypertension (2005)
5. Chronic kidney disease stage 3 (baseline Cr 1.8 mg/dL)
6. Hyperlipidemia
```
#### Past Surgical History (PSH)
**Include:**
- All surgeries and procedures
- Dates (year acceptable if exact date unknown)
- Complications if any
**Format:**
```
PSH:
1. CABG x4 (2019), complicated by post-op atrial fibrillation
2. Cholecystectomy (2015)
3. Appendectomy (childhood)
```
#### Medications
**Documentation:**
- Generic name preferred
- Dose, route, frequency
- Indication if not obvious
- Include over-the-counter medications
- Herbal supplements
- Note if patient unable to provide list
**Format:**
```
Medications:
1. Furosemide 40 mg PO daily (ran out 2 days ago)
2. Carvedilol 12.5 mg PO BID
3. Lisinopril 20 mg PO daily
4. Spironolactone 25 mg PO daily
5. Metformin 1000 mg PO BID
6. Atorvastatin 40 mg PO daily
7. Aspirin 81 mg PO daily
8. Multivitamin daily
```
#### Allergies
**Document:**
- Drug allergies with reaction
- Food allergies
- Environmental allergies
- NKDA if no known allergies
**Format:**
```
Allergies:
1. Penicillin → anaphylaxis (childhood)
2. Shellfish → hives
3. ACE inhibitors → angioedema
```
#### Family History (FH)
**Include:**
- First-degree relatives (parents, siblings, children)
- Age and health status or age at death and cause
- Relevant hereditary conditions
- Family history of presenting condition if relevant
**Format:**
```
Family History:
Father: CAD, MI age 58, alive age 85
Mother: Breast cancer, deceased age 72
Brother: Type 2 diabetes
Sister: Healthy
Children: 2 sons, both healthy
```
#### Social History (SH)
**Include:**
- Tobacco use (current, former, never; pack-years if applicable)
- Alcohol use (drinks per week, CAGE questions if indicated)
- Illicit drug use (current, former, never; type and route)
- Occupation
- Living situation (alone, with family, assisted living, etc.)
- Marital status
- Sexual history (if relevant)
- Exercise habits
- Diet
- Functional status
**Format:**
```
Social History:
Tobacco: Former smoker, quit 10 years ago (30 pack-year history)
Alcohol: 2-3 beers per week, denies binge drinking
Illicit drugs: Denies
Occupation: Retired electrician
Living situation: Lives at home with wife, 2-story house, bedroom upstairs
Marital status: Married
Exercise: Unable to exercise due to dyspnea
Diet: Low sodium diet (usually adherent)
Functional status: Independent in ADLs at baseline
```
#### Review of Systems (ROS)
**Purpose:** Systematic screening for symptoms by body system
**Requirements:**
- Minimum 10 systems for comprehensive exam
- Pertinent positives and negatives
- "All other systems reviewed and negative" acceptable if documented
**Systems:**
1. **Constitutional**: Fever, chills, night sweats, weight change, fatigue
2. **Eyes**: Vision changes, pain, discharge
3. **ENT**: Hearing loss, tinnitus, sinus problems, sore throat
4. **Cardiovascular**: Chest pain, palpitations, edema, claudication
5. **Respiratory**: Cough, dyspnea, wheezing, hemoptysis
6. **Gastrointestinal**: Nausea, vomiting, diarrhea, constipation, abdominal pain
7. **Genitourinary**: Dysuria, frequency, hematuria, incontinence
8. **Musculoskeletal**: Joint pain, swelling, stiffness, weakness
9. **Skin**: Rashes, lesions, itching, changes in moles
10. **Neurological**: Headache, dizziness, syncope, seizures, weakness, numbness
11. **Psychiatric**: Mood changes, depression, anxiety, sleep disturbance
12. **Endocrine**: Heat/cold intolerance, polyuria, polydipsia
13. **Hematologic/Lymphatic**: Easy bruising, bleeding, lymph node swelling
14. **Allergic/Immunologic**: Seasonal allergies, frequent infections
**Format:**
```
ROS:
Constitutional: Denies fever, chills. Reports fatigue and weight gain (8 lbs).
Cardiovascular: Reports dyspnea, orthopnea, lower extremity edema. Denies chest pain,
palpitations, syncope.
Respiratory: Denies cough, wheezing, hemoptysis.
Gastrointestinal: Denies nausea, vomiting, diarrhea, constipation, abdominal pain.
All other systems reviewed and negative.
```
#### Physical Examination
**General organization:**
- Vital signs first
- General appearance
- Systematic examination head-to-toe
**Vital signs:**
```
Vitals: T 98.2°F, BP 142/88, HR 105, RR 24, SpO2 88% on room air → 95% on 2L NC
Height: 5'10", Weight: 195 lbs (baseline 187 lbs), BMI 28
```
**System examinations:**
**General:** Well-developed, obese man in moderate respiratory distress, sitting upright in bed
**HEENT:**
- Head: Normocephalic, atraumatic
- Eyes: PERRLA, EOMI, no scleral icterus
- Ears: TMs clear bilaterally
- Nose: Nares patent, no discharge
- Throat: Oropharynx without erythema or exudates
**Neck:** Supple, no lymphadenopathy, JVP elevated to 12 cm, no thyromegaly
**Cardiovascular:**
- Inspection: No visible PMI
- Palpation: PMI laterally displaced
- Auscultation: Tachycardic regular rhythm, S3 gallop present, 2/6 holosystolic murmur at apex radiating to axilla
- Peripheral pulses: 2+ radial, 1+ dorsalis pedis bilaterally
**Pulmonary:**
- Inspection: Increased work of breathing, using accessory muscles
- Palpation: Tactile fremitus symmetric
- Percussion: Dullness to percussion at bilateral bases
- Auscultation: Bilateral crackles halfway up lung fields, no wheezes
**Abdomen:**
- Inspection: Obese, no distention
- Auscultation: Normoactive bowel sounds
- Percussion: Tympanic
- Palpation: Soft, non-tender, no masses, no hepatosplenomegaly
**Extremities:** 3+ pitting edema to mid-calf bilaterally, no cyanosis or clubbing
**Skin:** Warm and dry, no rashes
**Neurological:**
- Mental status: Alert and oriented to person, place, time
- Cranial nerves: II-XII intact
- Motor: 5/5 strength all extremities
- Sensory: Intact to light touch
- Reflexes: 2+ symmetric
- Gait: Deferred due to respiratory distress
- Cerebellar: Finger-to-nose intact
**Psychiatric:** Anxious affect appropriate to illness, normal thought process
#### Laboratory and Imaging
**Include:**
- All relevant labs with reference ranges
- Imaging studies with key findings
- ECG findings
- Other diagnostic tests
**Example:**
```
Laboratory Data:
CBC: WBC 8.5, Hgb 11.2 (L), Hct 34%, Plt 245
BMP: Na 132 (L), K 3.2 (L), Cl 98, CO2 30, BUN 45 (H), Cr 2.1 (H, baseline 1.8), glucose 145
Troponin: <0.04 (normal)
BNP: 1250 pg/mL (H, elevated)
Imaging:
Chest X-ray: Cardiomegaly, bilateral pleural effusions, pulmonary vascular congestion
consistent with volume overload
ECG: Sinus tachycardia at 105 bpm, left ventricular hypertrophy, no acute ST-T changes
```
#### Assessment and Plan
**Format:** Problem-based with numbered problem list
**Example:**
```
Assessment and Plan:
65-year-old man with history of CHF (EF 35%) presenting with acute decompensated
heart failure.
1. Acute decompensated heart failure (I50.23)
- NYHA Class IV symptoms
- Volume overload on exam and imaging
- Precipitated by medication non-adherence (ran out of furosemide)
- BNP elevated at 1250
Diagnostics:
- Echocardiogram to assess current EF and valvular function
- Daily weights and strict I/O
Therapeutics:
- Furosemide 40 mg IV BID, goal negative 1-2L daily
- Continue carvedilol, lisinopril, spironolactone
- Oxygen 2L NC, goal SpO2 >92%
- Low sodium diet (<2g/day), fluid restriction 1.5L/day
- Telemetry monitoring
Follow-up: Will reassess after diuresis, goal discharge in 3-5 days
2. Acute kidney injury on CKD stage 3 (N17.9, N18.3)
- Cr 2.1 from baseline 1.8, likely prerenal from poor forward flow
- Monitor daily, expect improvement with diuresis
- Hold nephrotoxic agents
3. Hypokalemia (E87.6)
- K 3.2, likely from prior diuretic use
- Replete K 40 mEq PO x1, then reassess
- Continue spironolactone for K-sparing effect
4. Hyponatremia (E87.1)
- Na 132, likely dilutional from volume overload
- Expect improvement with diuresis
- Fluid restriction as above
5. Type 2 diabetes mellitus (E11.9)
- Well-controlled
- Continue home metformin
- Monitor glucose while hospitalized
6. Coronary artery disease (I25.10)
- Stable, no acute coronary syndrome
- Continue aspirin, statin, beta-blocker
Code status: Full code
Disposition: Admit to telemetry floor
```
## Discharge Summary
### Purpose
- Communicate hospital care to outpatient providers
- Document hospital course and outcomes
- Ensure continuity of care
- Meet regulatory requirements (TJC, CMS)
### Timing
**Requirements:**
- Complete within 30 days of discharge (CMS)
- Many hospitals require within 24-48 hours
- Available at time of follow-up appointment
### Components
#### Header
- Patient demographics
- Admission date and discharge date
- Length of stay
- Attending physician
- Consulting services
- Primary care physician
#### Admission Diagnosis
Principal reason for hospitalization
#### Discharge Diagnosis
**Format:** Numbered list, prioritized
**Example:**
```
Discharge Diagnoses:
1. Acute decompensated heart failure
2. Acute kidney injury on chronic kidney disease stage 3
3. Hypokalemia
4. Hyponatremia
5. Coronary artery disease
6. Type 2 diabetes mellitus
```
#### Hospital Course
**Content:**
- Chronological narrative or problem-based
- Key events and interventions
- Response to treatment
- Procedures performed
- Consultations
- Complications
- Significant test results
**Example (brief):**
```
Hospital Course:
Mr. Smith was admitted with acute decompensated heart failure in the setting of
medication non-adherence. He was diuresed with IV furosemide with net negative
5 liters over 3 days, with significant improvement in dyspnea and resolution of
lower extremity edema. Echocardiogram showed persistent reduced EF of 30%, similar
to prior. Kidney function improved to baseline with diuresis. Electrolytes were
repleted and normalized. Patient was transitioned to oral furosemide on hospital
day 3 and remained stable. He was ambulating without dyspnea on room air by
discharge. Comprehensive heart failure education was provided.
```
#### Procedures
```
Procedures:
1. Echocardiogram transthoracic (hospital day 1)
```
#### Discharge Medications
**Format:**
- Complete list with instructions
- **NEW** medications highlighted
- **CHANGED** medications noted
- **DISCONTINUED** medications listed
**Example:**
```
Discharge Medications:
1. Furosemide 60 mg PO daily [INCREASED from 40 mg]
2. Carvedilol 12.5 mg PO BID [UNCHANGED]
3. Lisinopril 20 mg PO daily [UNCHANGED]
4. Spironolactone 25 mg PO daily [UNCHANGED]
5. Metformin 1000 mg PO BID [UNCHANGED]
6. Atorvastatin 40 mg PO daily [UNCHANGED]
7. Aspirin 81 mg PO daily [UNCHANGED]
```
#### Discharge Condition
```
Discharge Condition:
Hemodynamically stable, ambulatory, no supplemental oxygen requirement, euvolemic
on exam, baseline functional status restored.
```
#### Discharge Disposition
```
Discharge Disposition:
Home with self-care
```
#### Follow-up Plans
**Include:**
- Appointments scheduled
- Recommended follow-up timing
- Pending tests or studies at discharge
- Referrals made
**Example:**
```
Follow-up:
1. Cardiology appointment with Dr. Jones on [date] at [time]
2. Primary care with Dr. Smith in 1 week
3. Home health for vital sign monitoring and medication reconciliation
4. Repeat BMP in 1 week (arranged, lab slip provided)
```
#### Patient Instructions
**Include:**
- Activity restrictions
- Dietary restrictions
- Wound care (if applicable)
- Equipment or home services
- Monitoring instructions (daily weights, glucose, BP)
- Return precautions
**Example:**
```
Patient Instructions:
1. Weigh yourself daily every morning, call doctor if gain >2 lbs in 1 day or >5 lbs
in 1 week
2. Low sodium diet (<2 grams per day)
3. Fluid restriction 2 liters per day
4. Take all medications as prescribed, do not run out of medications
5. Activity: Resume normal activities as tolerated
6. Return to ER or call 911 if: severe shortness of breath, chest pain, severe swelling,
or other concerning symptoms
```
---
This reference provides comprehensive standards for patient clinical documentation including SOAP notes, H&P, and discharge summaries. Use these guidelines to ensure complete, accurate, and compliant clinical documentation.

585
skills/clinical-reports/references/peer_review_standards.md Normal file
View File

@@ -0,0 +1,585 @@
# Peer Review Standards for Clinical Manuscripts
## Overview of Clinical Manuscript Peer Review
### Purpose
Peer review ensures that clinical manuscripts meet standards for scientific rigor, ethical conduct, and clear communication before publication.
**Objectives:**
- Assess scientific validity and methodology
- Evaluate clinical significance
- Verify ethical compliance
- Ensure clarity and completeness
- Improve manuscript quality
**Types of peer review:**
- Single-blind (reviewer knows author, author doesn't know reviewer)
- Double-blind (both parties anonymous)
- Open peer review (both parties known)
- Post-publication peer review
### Reviewer Responsibilities
**Accept reviews only when:**
- Qualified in the subject area
- No conflicts of interest
- Adequate time available (typically 2-3 weeks)
- Can provide constructive, unbiased evaluation
**Maintain confidentiality:**
- Do not share manuscript content
- Do not use information for personal advantage
- Do not involve others without editor permission
**Provide timely review:**
- Complete within requested timeframe
- Notify editor promptly if unable to complete
## Case Report Review Criteria
### CARE Guideline Compliance
**Verify manuscript includes:**
- [ ] Title identifies it as case report
- [ ] Keywords provided (2-5)
- [ ] Structured or unstructured abstract
- [ ] Introduction explaining why case is novel
- [ ] Patient information (de-identified)
- [ ] Clinical findings
- [ ] Timeline of events
- [ ] Diagnostic assessment
- [ ] Therapeutic interventions
- [ ] Follow-up and outcomes
- [ ] Discussion with literature review
- [ ] Patient perspective (if applicable)
- [ ] Informed consent statement
### Novelty and Significance
**Assess:**
- Is this case truly novel or does it add to medical knowledge?
- What makes this case worth reporting?
- Is the condition rare or presentation unusual?
- Does it challenge existing knowledge?
- Are there clinical lessons that can be generalized?
**Red flags:**
- Common presentation of common condition
- Single case without unique features
- Overgeneralization from single case
- Lack of literature review showing novelty
### Privacy and Ethical Considerations
**Verify:**
- Informed consent obtained and documented
- Patient adequately de-identified (18 HIPAA identifiers removed)
- No identifiable images without explicit consent
- Dates removed or approximated
- Geographic information limited to state/country
- Age appropriate (exact age or range)
- Institutional identifiers removed
**Ethical concerns:**
- Missing consent documentation
- Identifiable information present
- Lack of IRB approval for retrospective chart review (if applicable)
- Vulnerable populations without additional protections
### Clinical Quality
**Diagnostic process:**
- Appropriate workup for presenting symptoms
- Differential diagnosis considered
- Logical progression to final diagnosis
- Adequate documentation of findings
**Treatment:**
- Evidence-based interventions
- Rationale for treatment choices
- Alternative treatments considered
- Appropriate monitoring and follow-up
**Outcome:**
- Clear description of clinical outcome
- Follow-up duration appropriate
- Complications documented
- Long-term outcome if available
### Literature Review
**Assess:**
- Adequate search of existing literature
- Similar cases identified and discussed
- Current understanding of condition reviewed
- Case appropriately contextualized
- References current and relevant
- Comparison to prior cases
### Writing Quality
**Structure:**
- Logical flow and organization
- CARE guideline structure followed
- Clear, concise writing
- Appropriate medical terminology
**Clarity:**
- Medical jargon explained
- Timeline clear and easy to follow
- Chronology of events logical
- Conclusions supported by case details
## Clinical Trial Manuscript Review Criteria
### Study Design and Methodology
**Assess:**
- Appropriate study design for research question
- Clear objectives and hypotheses
- Well-defined primary and secondary endpoints
- Adequate sample size with power calculation
- Randomization and blinding appropriate
- Control group appropriate
**Red flags:**
- Post-hoc changes to endpoints
- Underpowered study claiming equivalence
- Inappropriate statistical methods
- Lack of blinding when feasible
- Selection bias in enrollment
### CONSORT Compliance
**Verify:**
- Title identifies as randomized trial
- Structured abstract
- Trial registration number provided
- Protocol accessible
- CONSORT flow diagram included
- Baseline characteristics table
- All outcomes reported (not just significant ones)
- Adverse events reported
- Funding source disclosed
- Conflicts of interest declared
### Randomization and Allocation
**Assess:**
- Adequate sequence generation method
- Allocation concealment appropriate
- Baseline characteristics balanced
- Stratification factors specified
- Crossovers and protocol deviations documented
### Participant Flow
**Verify:**
- Number screened reported
- Exclusion reasons provided
- Number randomized clear
- Dropouts and reasons documented
- Lost to follow-up minimized and explained
- ITT and per-protocol analyses specified
- CONSORT diagram complete and accurate
### Outcome Measures
**Primary outcome:**
- Clearly defined a priori
- Clinically meaningful
- Appropriate for research question
- Measured reliably and validly
- Statistical analysis appropriate
**Secondary outcomes:**
- Pre-specified in protocol
- Analyzed appropriately
- Multiple comparison correction if needed
- Not over-interpreted if underpowered
**Exploratory outcomes:**
- Clearly labeled as exploratory or post-hoc
- Not given same weight as primary
- Hypothesis-generating, not confirmatory
### Statistical Analysis
**Assess:**
- Analysis plan specified before unblinding
- Appropriate statistical tests
- Assumptions verified (normality, etc.)
- Missing data handled appropriately
- Multiplicity adjustments when needed
- Confidence intervals provided
- Effect sizes reported
**Common issues:**
- p-hacking (selective reporting)
- Multiple testing without correction
- Inappropriate subgroup analyses
- Switching between ITT and per-protocol analyses
- Missing data ignored or improperly handled
### Safety Reporting
**Verify:**
- All adverse events reported
- Serious adverse events detailed
- Deaths fully described
- Causality assessed
- Laboratory abnormalities reported
- Discontinuations due to AEs documented
### Clinical Significance
**Assess:**
- Statistical significance vs. clinical significance
- Magnitude of effect clinically meaningful
- Number needed to treat (NNT) if applicable
- Benefit-risk ratio favorable
- Generalizability to practice
- Cost-effectiveness considerations
## Diagnostic Study Review Criteria
### STARD Guidelines (Standards for Reporting Diagnostic Accuracy Studies)
**Assess compliance:**
- Study design described
- Participant selection criteria
- Sampling method
- Data collection procedure
- Reference standard defined
- Index test described in detail
- Blinding addressed
- Flow of participants clear
- 2×2 table provided
- Diagnostic accuracy estimates
### Reference Standard
**Verify:**
- Appropriate gold standard used
- Same reference standard for all participants
- Reference standard performed regardless of index test result
- Time between index test and reference standard appropriate
- Independent interpretation of index test and reference standard
### Test Performance
**Required metrics:**
- Sensitivity and specificity
- Positive and negative predictive values (with prevalence)
- Likelihood ratios
- ROC curve and AUC (if continuous outcome)
- 95% confidence intervals for all estimates
**Consider:**
- Pre-test and post-test probabilities
- Clinical utility beyond accuracy
- Comparison to existing tests
- Cost and availability
### Spectrum and Verification Bias
**Assess:**
- Spectrum of disease severity included
- Avoiding spectrum bias (only severe cases)
- Verification bias avoided (all participants get reference standard)
- Differential verification avoided (different reference standards for different participants)
## Observational Study Review Criteria
### STROBE Guidelines (Strengthening the Reporting of Observational Studies in Epidemiology)
**For cohort, case-control, or cross-sectional studies, verify:**
- Title and abstract identify study design
- Background and rationale clear
- Objectives specified
- Study design present in methods
- Setting described
- Participants described
- Variables clearly defined
- Data sources and measurement detailed
- Bias addressed
- Study size justified
- Statistical methods described
- Results reported with effect sizes and CIs
### Exposure and Outcome Assessment
**Assess:**
- Exposure clearly defined
- Outcome clearly defined
- Measurement methods valid and reliable
- Blinding of assessors when possible
- Consistent measurement across groups
- Time relationship between exposure and outcome appropriate
### Confounding and Bias
**Verify:**
- Potential confounders identified
- Adjustment for confounders in analysis
- Residual confounding discussed
- Selection bias addressed
- Information bias considered
- Sensitivity analyses performed
### Causality
**Bradford Hill Criteria consideration:**
- Strength of association
- Consistency across studies
- Specificity
- Temporality (exposure precedes outcome)
- Biological gradient (dose-response)
- Plausibility
- Coherence with existing knowledge
- Experimental evidence
- Analogy
**Avoid:**
- Causal language for observational studies without strong evidence
- Confusing association with causation
## Systematic Review and Meta-Analysis Review Criteria
### PRISMA Guidelines
**Verify:**
- Title identifies as systematic review/meta-analysis
- Structured abstract
- Research question (PICO format)
- Protocol and registration (PROSPERO)
- Search strategy comprehensive
- Study selection process described
- Data extraction process
- Quality assessment of included studies
- Synthesis methods appropriate
- Results with forest plots
- Assessment of heterogeneity
- Publication bias assessed
- Certainty of evidence (GRADE)
### Search Strategy
**Assess:**
- Multiple databases searched
- Search terms comprehensive
- Limits and filters justified
- Gray literature considered
- Hand-searching of references
- Contact with authors for missing data
- Search reproducible
### Study Selection
**Verify:**
- Inclusion/exclusion criteria pre-specified
- Independent screening by ≥2 reviewers
- Disagreements resolved appropriately
- PRISMA flow diagram complete
- Excluded studies with reasons
### Quality Assessment
**Assess:**
- Appropriate quality assessment tool used
- RCTs: Cochrane Risk of Bias tool
- Observational: Newcastle-Ottawa Scale
- Diagnostic: QUADAS-2
- Independent quality assessment
- Results of quality assessment reported
- Quality incorporated into synthesis
### Statistical Methods
**For meta-analysis:**
- Fixed vs. random effects model justified
- Heterogeneity assessed (I², Q statistic)
- Forest plot provided
- Publication bias assessed (funnel plot, Egger's test)
- Sensitivity analyses performed
- Subgroup analyses pre-specified
### GRADE Assessment
**Certainty of evidence:**
- High: Very confident in effect estimate
- Moderate: Moderately confident
- Low: Limited confidence
- Very low: Very little confidence
**Factors decreasing certainty:**
- Risk of bias
- Inconsistency
- Indirectness
- Imprecision
- Publication bias
## Manuscript Quality Assessment
### Structure and Organization
**Assess:**
- Logical flow from introduction through discussion
- Sections appropriately organized
- Figures and tables support text
- Supplementary materials appropriate
### Writing Quality
**Clarity:**
- Clear, concise language
- Jargon minimized and defined
- Abbreviations defined at first use
- Consistent terminology
**Grammar and style:**
- Correct grammar and spelling
- Appropriate verb tense (past for study results, present for established facts)
- Active voice when appropriate
- Concise without sacrificing clarity
### References
**Verify:**
- Adequate number of references
- Current literature included
- Key papers cited
- References formatted correctly
- All citations in reference list and vice versa
- No excessive self-citation
### Tables and Figures
**Assess:**
- Appropriate for data type
- Clear labels and legends
- High quality images
- Can stand alone
- No redundancy with text
- Statistical notation correct
## Ethical Considerations in Review
### Conflicts of Interest
**Disclose and recuse if:**
- Personal relationship with authors
- Financial interest in outcome
- Competing research
- Strong bias for or against topic
- Institutional conflict
### Fair and Constructive Review
**Provide:**
- Balanced assessment of strengths and weaknesses
- Specific, actionable suggestions
- Respectful tone
- Objective evaluation
- Recognition of limitations of study design
**Avoid:**
- Personal attacks
- Dismissive language
- Demanding unreasonable revisions
- Expecting perfect study
- Imposing personal preferences over standards
### Confidentiality
**Maintain:**
- Do not share manuscript
- Do not discuss with colleagues without permission
- Do not use ideas or data
- Destroy copies after review
## Recommendation Categories
**Accept:**
- Manuscript meets publication standards
- Minor editing only
**Minor revisions:**
- Small issues that can be addressed
- No additional data required
- Typically one round of revision
**Major revisions:**
- Significant concerns requiring substantial changes
- May require additional analyses
- May require additional data or experiments
- Typically re-reviewed
**Reject:**
- Fundamental flaws that cannot be corrected
- Insufficient novelty or significance
- Unethical conduct
- Fraudulent data
**Reject and resubmit:**
- Study has potential but needs substantial work
- Essentially new submission after major changes
## Writing the Review Report
### Structure
**Summary:**
- Brief overview (2-3 sentences)
- Overall assessment
- Key strengths (2-3 points)
- Key weaknesses (2-3 points)
- Recommendation
**Major comments:**
- Numbered
- Significant issues affecting validity, interpretation, or impact
- Specific and actionable
- Prioritized
**Minor comments:**
- Numbered
- Editorial, formatting, or clarification issues
- Line-specific comments
- Table/figure comments
### Tone and Language
**Use:**
- Professional, collegial tone
- "The authors state..." not "You state..."
- "This study shows..." not "Your study shows..."
- Constructive criticism
- Suggestions for improvement
**Avoid:**
- Harsh or dismissive language
- Personal pronouns
- Sarcasm
- Vague criticism
- Unreasonable demands
### Specific and Actionable Feedback
**Good:**
"The sample size calculation (page 8) does not account for expected dropout rate. Please revise to include expected dropout and explain how this affects enrollment targets."
**Poor:**
"Sample size is inadequate."
**Good:**
"Figure 2 would be clearer if error bars represented 95% CI rather than SEM. Please revise and update figure legend accordingly."
**Poor:**
"Figure 2 is confusing."
---
This reference provides comprehensive peer review standards for clinical manuscripts including case reports, clinical trials, diagnostic studies, observational studies, and systematic reviews. Use these criteria to conduct thorough, constructive peer reviews.

577
skills/clinical-reports/references/regulatory_compliance.md Normal file
View File

@@ -0,0 +1,577 @@
# Regulatory Compliance for Clinical Reports
## HIPAA (Health Insurance Portability and Accountability Act)
### Overview
HIPAA Privacy Rule protects individually identifiable health information (Protected Health Information, PHI). All clinical reports must comply with HIPAA requirements for privacy and security.
### Protected Health Information (PHI)
**Definition:** Individually identifiable health information held or transmitted by covered entities or business associates in any form or medium.
**Covered Entities:**
- Healthcare providers
- Health plans
- Healthcare clearinghouses
**Business Associates:**
- Third parties providing services involving PHI
- Require Business Associate Agreement (BAA)
### 18 HIPAA Identifiers
These identifiers must be removed for Safe Harbor de-identification:
1. **Names**
2. **Geographic subdivisions smaller than state** (except first 3 digits of ZIP if >20,000 people)
3. **Dates** (except year) - birth, admission, discharge, death
4. **Telephone numbers**
5. **Fax numbers**
6. **Email addresses**
7. **Social Security numbers**
8. **Medical record numbers**
9. **Health plan beneficiary numbers**
10. **Account numbers**
11. **Certificate/license numbers**
12. **Vehicle identifiers and serial numbers**
13. **Device identifiers and serial numbers**
14. **Web URLs**
15. **IP addresses**
16. **Biometric identifiers** (fingerprints, voiceprints)
17. **Full-face photographs and comparable images**
18. **Any other unique identifying characteristic or code**
### De-identification Methods
#### Method 1: Safe Harbor
Remove all 18 identifiers AND have no actual knowledge that remaining information could be used to identify the individual.
**Implementation:**
- Remove/redact all 18 identifiers
- Ages over 89 must be aggregated to "90 or older"
- Dates can keep year only
- Geographic areas can include state only
- Documentation that no identifying information remains
#### Method 2: Expert Determination
Statistical/scientific analysis demonstrating that risk of re-identification is very small.
**Requirements:**
- Performed by qualified statistician or expert
- Documented analysis methods
- Conclusion that re-identification risk is very small
- Maintained documentation
### HIPAA Minimum Necessary Standard
**Principle:** Use, disclose, and request only the minimum PHI necessary to accomplish purpose.
**Exceptions:**
- Treatment purposes (providers need full information)
- Patient-authorized disclosures
- Required by law
**Implementation:**
- Role-based access controls
- Purpose-specific disclosures
- Limited data sets when feasible
### Patient Authorization
**When required:**
- Uses/disclosures beyond treatment, payment, operations (TPO)
- Marketing purposes
- Sale of PHI
- Psychotherapy notes
- Research (unless waiver obtained)
**Required elements of authorization:**
- Specific description of PHI to be used/disclosed
- Person(s) authorized to make disclosure
- Person(s) to receive information
- Purpose of disclosure
- Expiration date or event
- Patient signature and date
- Right to revoke
- Potential for re-disclosure by recipient
### HIPAA Security Rule (Electronic PHI)
**Administrative Safeguards:**
- Security management process
- Workforce security
- Information access management
- Security awareness and training
- Security incident procedures
**Physical Safeguards:**
- Facility access controls
- Workstation use and security
- Device and media controls
**Technical Safeguards:**
- Access control
- Audit controls
- Integrity controls
- Transmission security
### Breach Notification Rule
**Breach definition:** Unauthorized acquisition, access, use, or disclosure of PHI that compromises security or privacy.
**Notification requirements:**
- **Individual notification:** Without unreasonable delay, no later than 60 days
- **Media notification:** If breach affects >500 residents of a state or jurisdiction
- **HHS notification:** Within 60 days if >500 individuals; annually if <500
- **Business associate notification to covered entity:** Without unreasonable delay
**Content of notification:**
- Description of breach
- Types of information involved
- Steps individuals should take to protect themselves
- What entity is doing to investigate/mitigate
- Contact procedures for questions
### Penalties for HIPAA Violations
**Civil penalties (per violation):**
- Tier 1: $100-$50,000 (unknowing)
- Tier 2: $1,000-$50,000 (reasonable cause)
- Tier 3: $10,000-$50,000 (willful neglect, corrected)
- Tier 4: $50,000-$1.9M (willful neglect, not corrected)
**Criminal penalties:**
- Knowingly obtaining PHI: Up to $50,000 and/or 1 year
- Under false pretenses: Up to $100,000 and/or 5 years
- Intent to sell/transfer/use for commercial advantage: Up to $250,000 and/or 10 years
### Research and HIPAA
**HIPAA authorization for research:**
- Specific to research study
- Describes PHI to be used
- States that PHI may not be necessary for treatment
**Waiver of authorization:**
- IRB or Privacy Board approval
- Minimal risk to privacy
- Research could not practically be conducted without waiver
- Research could not practically be conducted without access to PHI
- Plan to protect identifiers
- Plan to destroy identifiers when appropriate
- Written assurances
**Limited data sets:**
- Remove 16 of 18 identifiers (may keep dates and geographic subdivisions)
- Data use agreement required
- Only for research, public health, or healthcare operations
## 21 CFR Part 11 (Electronic Records and Electronic Signatures)
### Scope
FDA regulation establishing criteria for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records.
**Applies to:**
- Clinical trial data
- Regulatory submissions
- Manufacturing records
- Laboratory records
- Any record required by FDA regulations
### Electronic Records Requirements
**System validation:**
- Validation documentation
- Accuracy, reliability, consistent performance
- Ability to discern invalid or altered records
**Audit trails:**
- Secure, computer-generated, time-stamped audit trail
- Record of:
- Date and time of entry/modification
- User making change
- Previous values changed
- Cannot be modified or deleted by users
- Retained for records retention period
**Operational checks:**
- Authority checks (user authorization)
- Device checks (valid input devices)
- Education and training
- Confirmation of intent (e.g., "Are you sure?")
**Record retention:**
- Electronic copies as accurate as paper
- Protection from loss (backups)
- Protection from unauthorized access
- Ability to produce readable copies for FDA inspection
### Electronic Signatures Requirements
**General requirements:**
- Unique to one individual
- Not reused or reassigned
- Verification of identity before establishing
- Certification to FDA that electronic signatures are legally binding
**Components:**
- Unique ID
- Password or biometric
- Two distinct components when executed
**Controls:**
- Session timeout for inactivity
- Periodic password changes
- Prevention of password reuse
- Detection and reporting of unauthorized use
- Secure storage of passwords
- Unique electronic signatures (not shared)
**Electronic signature manifestations:**
Must include:
- Printed name of signer
- Date and time of signing
- Meaning of signature (e.g., review, approval, authorship)
### Closed vs. Open Systems
**Closed system:**
- Access limited to authorized individuals
- Within a single organization
- Less stringent requirements
**Open system:**
- Not controlled by persons responsible for content
- Accessible to unauthorized persons
- Requires additional measures:
- Encryption
- Digital signatures
- Other authentication/security measures
### Hybrid Systems (Paper + Electronic)
**Requirements:**
- Clear procedures for hybrid system use
- Maintain record integrity
- Paper records linked to electronic
- Cannot delete electronic records after printing
- Must preserve audit trails
### Legacy Systems
**Grandfather clause:**
- Systems in use before August 20, 1997 may be grandfathered
- Must demonstrate trustworthiness without full Part 11 compliance
- Must validate and document reliability
- Should have migration plan to compliant system
## ICH-GCP (Good Clinical Practice)
### Overview
International ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects.
**Purpose:**
- Protect rights, safety, and well-being of trial subjects
- Ensure credibility of clinical trial data
**Regulatory adoption:**
- FDA recognizes ICH-GCP (E6)
- Required for studies supporting regulatory submissions
### Principles of ICH-GCP
**1. Ethics:** Clinical trials should be conducted in accordance with ethical principles (Declaration of Helsinki, local laws)
**2. Risk-benefit:** Trials should be scientifically sound with favorable risk-benefit ratio
**3. Rights and welfare:** Rights, safety, and well-being of subjects take precedence over science and society
**4. Available information:** Trials should use available nonclinical and clinical information
**5. Quality:** Trials should be scientifically sound and described in clear, detailed protocol
**6. Compliance:** Trials should comply with approved protocol
**7. Qualified personnel:** Trials should be conducted by qualified individuals
**8. Informed consent:** Freely given informed consent should be obtained from each subject
**9. Privacy:** Confidentiality of subject records must be protected
**10. Quality assurance:** Systems with procedures ensuring quality of data generated
**11. Investigational products:** Manufactured, handled, and stored per GMP; used per approved protocol
**12. Documentation:** Documentation systems should allow accurate reporting, interpretation, and verification
**13. Quality management:** Sponsor should implement quality management system
### Essential Documents
**Before trial initiation:**
- Investigator's Brochure
- Protocol and amendments
- Sample CRF
- IRB/IEC approval
- Informed consent forms
- Financial disclosure
- Curriculum vitae of investigators
- Normal laboratory values
- Certifications (lab, equipment)
- Decoding procedures for blinded trials
- Monitoring plan
- Sample labels
- Instructions for handling investigational products
**During trial:**
- Updates to investigator's brochure
- Protocol amendments and approvals
- Continuing IRB review
- Informed consent updates
- Curriculum vitae updates
- Monitoring visit reports
- Source documents
- Signed/dated consent forms
- CRFs
- Correspondence with regulatory authorities
**After trial:**
- Final report
- Documentation of investigational product destruction
- Samples of labels and labeling
- Post-study access to investigational product (if applicable)
### Investigator Responsibilities
**Qualifications:**
- Qualified by education, training, and experience
- Has adequate resources
- Has adequate time
- Has access to subjects
**Compliance:**
- Conduct trial per protocol
- Obtain IRB approval before trial
- Obtain informed consent
- Report adverse events
- Maintain essential documents
- Allow monitoring and auditing
- Retain records
**Safety reporting:**
- Immediately report SAEs to sponsor
- Report to IRB per requirements
- Report to regulatory authority per requirements
### Source Documentation
**Source documents:**
- Original documents, data, and records
- Examples: hospital records, clinical charts, laboratory notes, ECGs, pharmacy records
- Must support data in CRFs
**Source data verification (SDV):**
- Comparison of CRF data to source documents
- Required by monitors
- Can be 100% or risk-based sampling
**Good documentation practice:**
- Contemporaneous (record in real-time or soon after)
- Legible
- Indelible
- Original (or certified copy)
- Accurate
- Complete
- Attributable (signed/initialed and dated)
- Not retrospectively changed without documentation
**Corrections to source:**
- Single line through error
- Reason for change
- Date and initials
- Original entry still legible
- Never use correction fluid/whiteout
- Never obliterate original entry
### Record Retention
**Minimum retention:**
- 2 years after last approval of marketing application (US)
- At least 2 years after formal discontinuation of clinical development
- Longer if required by local regulations
- 25 years for some countries (e.g., Japan for new drugs)
**Documents to retain:**
- Protocols and amendments
- CRFs
- Source documents
- Signed informed consents
- IRB correspondence
- Monitoring reports
- Audit certificates
- Regulatory correspondence
- Final study report
## FDA Regulations
### 21 CFR Part 50 (Informed Consent)
**Elements of informed consent:**
1. Statement that study involves research
2. Description of purpose, duration, procedures
3. Experimental procedures identified
4. Reasonably foreseeable risks or discomforts
5. Benefits to subject or others
6. Alternative procedures or treatments
7. Confidentiality protections
8. Compensation and treatments for injury (if >minimal risk)
9. Who to contact for questions
10. Statement that participation is voluntary
11. Statement that refusal will involve no penalty or loss of benefits
12. Statement that subject may discontinue at any time
**Additional elements (when appropriate):**
- Unforeseeable risks to subject or embryo/fetus
- Circumstances of study termination by investigator
- Additional costs to subject
- Consequences of withdrawal
- New findings that may affect willingness to participate
- Approximate number of subjects
**Documentation:**
- Written consent required (unless waived)
- Copy provided to subject
- Subject or legally authorized representative must sign
- Person obtaining consent must sign
- Date of consent
**Vulnerable populations:**
- Children: Parental permission + assent (if capable)
- Prisoners: Additional protections
- Pregnant women: Additional protections for fetus
- Cognitively impaired: Legal representative consent
### 21 CFR Part 56 (IRB Standards)
**IRB composition:**
- At least 5 members
- Varying backgrounds
- At least one scientist
- At least one non-scientist
- At least one member not affiliated with institution
- No member may participate in review of study in which member has conflicting interest
**IRB review criteria:**
- Risks minimized
- Risks reasonable in relation to benefits
- Selection of subjects equitable
- Informed consent obtained and documented
- Data monitoring when appropriate
- Privacy and confidentiality protected
- Additional safeguards for vulnerable populations
**IRB review types:**
- Full board review
- Expedited review (certain categories of minimal risk)
- Exempt (certain categories)
**Continuing review:**
- At least annually
- More frequent if determined by IRB
- Review of progress, new information, consent process
**Documentation:**
- Written procedures
- Meeting minutes
- Review determinations
- Correspondence
- Retention of records for 3 years
### 21 CFR Part 312 (IND Regulations)
**IND requirements:**
- Investigator's Brochure
- Protocol(s)
- Chemistry, manufacturing, and controls information
- Pharmacology and toxicology information
- Previous human experience
- Additional information (if applicable)
**IND amendments:**
- Protocol amendments
- Information amendments
- Safety reports
- Annual reports
**Safety reporting:**
- IND safety reports (7-day and 15-day)
- Fatal or life-threatening unexpected: 7 days (preliminary), 15 days (complete)
- Other serious unexpected: 15 days
- Annual safety reports
**General investigational plan:**
- Rationale for drug or study
- Indications to be studied
- Approach to evaluating drug
- Kinds of trials planned (Phase 1, 2, 3)
- Estimated duration of study
## EU Clinical Trials Regulation (CTR)
**EU CTR 536/2014** (replaced Clinical Trials Directive 2001/20/EC)
**Key requirements:**
- Single submission portal (CTIS - Clinical Trials Information System)
- Single assessment by multiple member states
- Transparency requirements (EudraCT database)
- Public disclosure of clinical trial results
- Layperson summary of results required
**Timelines:**
- Assessment: 60 days (Part I), additional time for Part II
- Substantial modifications: 38 days
- Safety reporting: Within specified timelines to EudraVigilance
## Good Documentation Practice (GDP)
### Principles
**ALCOA-CCEA:**
- **A**ttributable: Who performed action and when
- **L**egible: Readable and permanent
- **C**ontemporaneous: Recorded when performed
- **O**riginal: First capture of information (or certified copy)
- **A**ccurate: Correct and truthful
Additional:
- **C**omplete: All data captured
- **C**onsistent: Chronological sequence, no discrepancies
- **E**nduring: Durable throughout retention period
- **A**vailable: Accessible for review when needed
### Data Integrity
**MHRA (UK) data integrity guidance:**
- Data governance (ownership, quality)
- Risk assessment
- Change management
- Training
- Regular audit
**Common data integrity issues:**
- Back-dating of records
- Deletion or hiding of data
- Repeat testing without documentation
- Transcription errors
- Missing metadata
- Inadequate audit trails
---
This reference provides comprehensive guidance for regulatory compliance in clinical reports and clinical trials, including HIPAA, FDA regulations, ICH-GCP, and EU requirements. Ensure all clinical documentation adheres to applicable regulations.